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Obesity is recognized as a top ten global health problem by the World Health 
Organisation (WHO). Dietary habits are one of the main contributing factors to 
obesity. As recently proven, recruitment of progenitors from the bone marrow also 
contributes to obesity. Thus, obesity is now considered to occur via mechanisms of 
hypertrophy and hyperplasia. In this in vitro study, we characterize lipidome changes 
during adipogenesis of mesenchymal stem cells (MSC) using thin layer 
chromatography and sensitive mass spectrometry.  
 
The lipid profiles of MSC undergoing adipogenesis revealed that in spite of the 
expected increase in triacylglycerols (TAG), there is also a surprising decrease in 
phospholipids during adipogenesis. This decrease appears to be counterintuitive at 
first. During adipogenic differentiation, the cells hypertrophy (grow in size). Thus, 
one expects to see increased phospholipids, so as to form the larger plasma 
membrane required to envelope the cellular contents.  However, this in turn implies 
that lipids perform only structural functions. Hence, our data also support a more 
dynamic role of lipids during cellular function.  
 
The gene expression levels of lipins 1, 2 and 3 and phospholipases (PLA1A, PLA2 
G4a, PLA2 G6 and PLB) demonstrated that these proteins may be responsible for the 
observed decrease in phospholipids. The progressive increase in TAG and the 
corresponding decrease in phospholipids coupled with the upregulation of lipin 1 
suggest that there is a shift in the phospholipids and TAG biosynthetic pathway that 
favours the synthesis of TAG. In addition, the upregulation of PLA2 G4a and PLA2 
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G6 demonstrates that the decrease in phospholipids may be due to increased 
hydroxylation by these enzymes.  
 
Despite the general decrease in phospholipids, phosphatidylglycerol (PG) is the 
unique class of phospholipids that exhibited an overall increase. The increase in PG 
may indicate an increase in mitochondria, which is exemplified through the transient 
increase in voltage-dependent anion channel (VDAC) protein as adipogenesis 
progresses. In addition, there are some species of phospholipids that increased 
overtime. Similarly, TAG species that display progressive increase encompass 
similar characteristics to phospholipids types that increase overtime. Most of them 
are made up of monounsaturated fatty acids (MUFA). This finding suggests that 
there is preferential incorporation of MUFA to TAG and phospholipids and that this 
process is occurring via the de novo pathway.  
 
In summary, lipid profiling of MSC undergoing adipogenesis presents the unique 
lipid fingerprints of cells at distinct differentiative stages. In-depth analysis of the 
abundant information acquired reveals that lipids are more than just structural and 
storage entities; they also play a more dynamic role in cellular functions. As a result, 
this yields interesting and novel observations, thus enables one to venture into 
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1.1 Mesenchymal stem cells (MSC) 
1.1.1 Definition of stem cells 
Stem cells (SC) are defined functionally as cells that have the capacity to self-renew 
and give rise to differentiated progeny (Weissman et al., 2001; Smith, 2001). Their 
fate choice is highly regulated by both intrinsic signals and the external 
microenvironment (Odorcico et al., 2001).  
 
1.1.2 Criteria of being stem cells 
Essentially, stem cells need to satisfy three criteria. Firstly, they possess the ability to 
self renew, which is defined as having the capability to replicate in an/a unlimited or 
prolonged fashion, thereby maintaining the stem cell pool. There are two schools of 
thought for stem cells regeneration (Watt & Hogan, 2000). One, known as invariant 
asymmetric division, involves a stem cell undergoing asymmetric cell division to 
give rise to one daughter stem cell and one daughter cell that differentiates into a 
specific lineage (Figure 1-1A). The other theory (populational asymmetric division) 
describes how a stem cell  undergoes cell division to form daughter cells with 
different fates, such as becoming daughter stem cells or daughter progenitor cells 
with different differentiation abilities depending on the factors they are exposed to 
(Figure 1-1B).  
 
Secondly, stem cells have a certain degree of potency within them where they 
undergo lineage commitment and differentiate into one or more differentiated cell 
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types of distinct morphology and gene expression pattern. Mesenchymal stem cells 
(MSC) are multipotent as they are able to differentiate into more than one 
differentiated cell type. However, unlike the pluripotent embryonic stem cells (ESC), 
MSC acquire tissue specific, restricted differentiation abilities. The differentiation 
process begins with the cell entering a transient state of rapid proliferation. After 
exhausting its proliferative potential, the cell exits the proliferative cycle and enters 
the terminal differentiation programme (Potten et al., 1979). 
 
Lastly, stem cells have the ability to repopulate a given tissue in vivo. In order to do 
this, homing to a given tissue, via interplay of chemokines and cytokines, is 
necessary. Upon reaching the tissue of interest, they will respond to specific cues and 
differentiate into cell types of that tissue. Consequently, the differentiated cells will 
take on the function of that tissue. For instance, transplantation of a single murine 
hematopoietic stem cell (HSC) into lethally irradiated animals leads to complete 
reconstitution of all hematopoietic cell types. Consistent with its stem cell nature, 
this hematopoietic reconstitution capability is maintained with serial transplantation 
(Ogawa et al., 1996). 
 
Figure  1-1: Different theories of stem cell division. 
A) Invariant asymmetric division.    B) Populational asymmetric division.  




1.1.3 Isolation of MSC 
MSC were first identified by Fridenshtein in 1966 and subsequent works illustrate 
the ability of MSC to form fibroblast-like colonies that could give rise to adipocytes 
and osteoblasts in vitro (Fridenshtein 1982; Fridenshtein et al., 1970; Fridenshtein et 
al., 1966). Cells with MSC-liked properties have been isolated from multiple tissues 
such as the periosteum (Fukumoto et al., 2003; O’Driscoll et al., 2001; Nakahara et 
al., 1990; Zarnett & Salter, 1989), trabecular bone (Tuli et al., 2003; Noth et al., 
2002; Sottile et al., 2002),), synovium (De Bari et al., 2001), skeletal muscle 
(Jankowski et al., 2002), deciduous teeth (Miura et al., 2003) and lungs (Noort et al., 
2002). Availability of these MSC-liked cells in a variety of adult tissues raises the 
question on the niche of MSC, their migration abilities and differentiation stimuli 
(Barry & Murphy, 2004). Nevertheless, isolation of MSC from bone marrow 
aspirates (Oswald et al., 2004; Pittenger et al., 1999) and adipose tissue (De ugarte et 
al., 2003; Dragoo et al., 2003; Wickham et al., 2003; Gronthos et al., 2001; Zuk et 
al., 2001) have been the most well-studied. As tissue specimen from these areas are 
easily available and the techniques of isolating MSC from these tissues and in vitro 
expansion and maintenance of these cells have been well-established.  
 
The mononuclear cell fraction from either bone marrow aspirates or adipose tissue is 
isolated via density gradient centrifugation and plated. Non-adherent cells are 
removed during the subsequent passaging process. Colony forming unit assay (CFU) 
(Pittenger et al., 1999) coupled with flow cytometric analysis based on defined 
antigenic determinants (Gronthos et al., 2003) are performed to obtain a more 
homogenous population of MSC. Unlike the well-characterised HSC where there 
exist surface markers that can isolate HSC specifically (Wolf et al., 1993; Sutherland 
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et al., 1989; Spangrude et al., 1988), the list of antigenic MSC markers used is not as 
well-defined as their neighbours HSC (Pittenger & Martin, 2004; Devine, 2002). 
Thus, determining the tripotentiality nature (adipogenic, osteogenic and 
chondrogenic potential)) of MSC is an additional measure to ensure that the isolated 
cells are indeed MSC (Dominici et al., 2006).  
 
1.1.4 MSC functions and their potential 
Adipogenic differentiation is induced by employing a combination of insulin, iso-
butyl-methylxanthine (IBMX), dexamethasone (Dex) and a peroxisome proliferator-
activated receptor γ (PPARγ) agonist (Pittenger et al., 1999). After 7 days of 
adipogenic induction, lipid droplets (LD) accumulate within the cells which can be 
stained with lipophilic dyes consistent with the adoption of adipocyte phenotype 
(Ramirez-Zacarias et al., 1992).  
 
Osteogenic differentiation of MSC is performed by treating the cells with Dex, L-
ascorbic acid and β-glycerophosphate (Pittenger et al., 1999). Two to three weeks 
later, aggregates or nodules of calcium deposition are observed through Alizarin red 
and Von Kossa staining. Alkaline phosphatase activity also increased 4-10 folds 
(Jaisval et al., 1997) and specific osteogenic gene markers, such as osteocalcin and 
osteopontin are expressed.  
 
In chrondrogenesis, cells are centrifuged to form a “pelleted micromass” which is 
cultured in serum free media supplemented with transforming growth factor-β3 
(TGF-β3) (Mackay et al., 1998). The cell pellet develops to possess a multilayered 
matrix-rich morphology, whereby the extracellular domain is rich in proteoglycans 
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and collagen types II and IV (Muraglia et al., 2000). Alcian blue staining can be used 
to confirm the presence of proteoglycans in the cell pellets.  
 
Besides the aforementioned three lineages, MSC also have the ability to differentiate 
into cardiomyocytes, skeletal myocytes and smooth muscle cells (Pittenger et al., 
1999; Wakitani et al., 1995). In addition, MSC display some forms of plasticity (the 
ability of adult stem cells to acquire mature phenotypes that are different from their 
tissue of origin) (Grove et al., 2004). Examples include MSC giving rise to cells of a 
neuronal phenotype, resembling astrocytes, glial cells and neuronal cells (Woodbury 
et al., 2000; Kopen et al., 1999) and MSC’s ability to transdifferentiate into cell 
types of different embryonic dermal origin (Tocci & Forte, 2003). However, 
functionality of these neuronal cell types and transdifferentiated cells remains to be 
proven.  
 
Apart from the multipotency of MSC, MSC also secrete an array of bioactive 
molecules that can have profound effects on the local microenvironment. For 
instance, MSC secrete cytokines that assist in the proliferation and differentiation of 
HSC (Azizi et al., 1998; Majumdar et al., 1998). In addition to the trophic effects of 
MSC, the presence of adhesion molecules on the surface of MSC also provide 
stromal support to HSC both in the in vivo and in vitro systems (Mourcin et al., 
2005; Kim et al, 2004; Maitra et al., 2004; Angelopoulou et al., 2003; Pittenger et 
al., 1999). As a result, MSC can be used to promote allogenic HSC engraftment. 
Intravenous administration of peripheral blood progenitor cells together with MSC in 
a group of breast cancer patients (undergoing high dose of chemotherapy) yield rapid 




The trophic effects of MSC coupled with its mulitpotency display the effectiveness 
of MSC as a therapeutic tool for the restoration of damaged or diseased tissue (i.e. 
mesodermal defect repair and disease management). For instance, Young and 
colleagues illustrate the effectiveness of rabbit MSC in regenerating severed tendon 
in rabbit models (Young et al., 1998). Besides this, there are reports exhibiting the 
promise of MSC in bringing about functional improvement of cardiac function in 
baboon myocardial infarction model (Tomo et al., 2002; Wang et al., 2000). Stamm 
et al. demonstrate that delivery of bone marrow cells into infarct zone of patients 
result in dramatic improvement in heart function (Stamm et al., 2003). Literatures 
display that administration of MSC lead to specific migration to site of injury and 
brought about enhanced cardiac function and regeneration of bone (Shake et al., 
2002; Orlic et al., 2001; Jackson et al., 2001). 
Besides this, MSC elicit immunosuppressive effects. MSC lack major 
histocompatibility class (MHC) II, CD40, CD40 ligand, CD80 and CD86 (Kumar et 
al., 2008; Deans & Moseley, 2000; Tse et al., 2000). Despite the expression of MHC 
class II when MSC are treated with interferon-γ (IFN-γ), T cells remained inactivated 
due to the lack of co-stimulatory molecules, such as CD80, CD86, CD40 and CD40 
ligand. Consequently, anergic T cells prevail (Romieu-Mourez et al., 2007; Le Blanc 
et al., 2003). Furthermore, papers have established the abilities of MSC to disrupt the 
function and maturation of dendritic cells and B cells (Corcione et al., 2006; Nauta et 
al., 2006; Zhang et al., 2004). Hence, MSC can be used to help reduce the incidence 
and severity of Graft-versus-host disease (GVHD). For example, HSC 
transplantation in murine models together with varying doses of MSC prevents 
GVHD and increases survival rate in mice (Sotiropoulou et al., 2006; Chung et al., 
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2004). Patients undergoing allogenic bone marrow transplantation along with MSC 























1.2.1 Definition and relevance 
Adipogenesis is the recruitment of precursor cells and under appropriate cues 
differentiate to mature fat cells (i.e. adipocytes) (Hausman et al., 2001; Rosen & 
Spiegelman, 2000). Preadipocytes are operationally defined as cells isolated from the 
stromovascular fraction of fat depots that possess the ability to progress towards an 
adipocytic cell fate when adipogenic stimulus is provided. Adipocytes store energy 
in the form of triacylglycerols (TAG) and cholesterol esters that are contained inside 
lipid droplets composed of a neutral core enveloped by a protein coated single 
phospholipid layer (Martin & Parton, 2005). The ability of adipose tissue to store 
excess energy has been strongly selected during evolution, thus they play a vital role 
in energy homeostasis. Diseases such as obesity and non-insulin dependent diabetes 
mellitus (Type 2 diabetes) are of increasing interest due to their increasing 
prevalence globally (Zimmet et al., 2001). With the explosion of information on the 
metabolic disorders linked to obesity, there is added sense of urgency to recognize 
the key nodal points of energy balance. Thus, understanding adipose cell 
development and physiology is of utmost importance.  
 
1.2.2 Obesity and associated diseases 
Obesity is a condition characterized by an abnormal or excessive accumulation of fat 
in the body, especially in the adipose tissue, to a magnitude that results in adverse 
health consequences (Spiegelman & Flier, 2001; World Health Organisation (WHO), 
1995). At the moment, the gold standard for determining obesity is via body mass 
index (BMI), which is defined as the weight in kilograms divided by the square of 
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the height in metres (kg/m2). An individual is obese when the BMI is 30 (kg/m2) and 
higher. However, Asians have higher proportion of body fat as compared to 
Caucasians of the same age, gender and BMI (Wang et al., 1994). Hence, the cut off 
is lowered to 25 for Asians. In Singapore, BMI is used to assess the predisposition to 
obesity related diseases. Individuals with BMI between 23 and 27.4 pose moderate 
risk, while those with 27.5 and higher are at a higher risk (Health Promotion Board, 
2005). 
 
According to the WHO, obesity has been viewed as a worldwide epidemic (WHO, 
2008).  Contrary to conventional belief, obesity is affecting not only the developed 
and affluent societies, but also emerging countries too (Monteiro et al., 2007; 
Popkin, 2002; Wu et al., 2002). The prevalence of obesity adopts a rising trend. In 
1995, an estimated 200 million adults are classified as obese. By 2000, this number 
increased to 300 million. In 2005, WHO reports that there are at least 400 million 
obese adults globally and project this value to exceed 700 million by 2015 (WHO, 
2008, 2003).  
 
Obese individual have been shown to be more susceptible to diseases such as 
cardiovascular diseases, hypertension, stroke and certain forms of cancer. The 
Framingham Heart study demonstrates that with every 1 increment of the BMI, there 
is an increased risk of heart failure of 5% for men and 7% for women (Kenchaiah et 
al., 2002), thus implying that the increased risk of heart failure is associated with the 
increase in BMI. By elevating BMI from 25 to 30 and beyond, the relative risk for 
hypertension increases from 1.48 to 2.23 for men and 1.70 to 2.63 for women 
(Wilson et al., 2002). According to the North Manhattan study, subjects with greater 
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abdominal obesity, measured by the waist to hip ratio, experience enhanced risk in 
ischemic stroke and their respective odds ratio increases from 1.0 to 3.3 (Suk et al., 
2003). In the United States (US), an estimated 14-20% of cancer deaths are attributed 
to obesity (Calle et al., 2003). With the emerging endocrine role of adipose tissue, 
adipokines and other secretory products exert profound effects on normal metabolic 
homeostasis (Garg, 2006), leading to the elucidation of metabolic disorders. This 
includes dyslipidemia, insulin resistance and Type 2 diabetes, which are collectively 
termed as “metabolic syndrome X”, “insulin resistance syndrome” or “Reaven 
syndrome” (Petrie et al., 1998; Reaven, 1995; Reaven, 1993). Besides the 
detrimental health consequences of obesity, there are also economic costs imposed 
on societies (Runge, 2007; Yach et al., 2006). In the US, obesity accounts for 1.2 % 
of the gross domestic product (GDP) (US Department of Human health and services, 
2001).  
 
Increasing sedentary lifestyle and rapidly changing dietary habits, in favour of fat, 
caloric sweeteners and animal source food, result in major energy imbalance. The 
excess energy is stored as TAG in adipose tissue resulting in adipocyte hypertrophy. 
Hyperplasia of adipocyte is also an etiology of obesity especially in extreme form of 
obesity in humans and rodents (Hirsch et al., 1989). It is in these morbidly obese 
patients that prognosis is the poorest (Bjorntorp et al., 1982). Some animal studies 
suggest that adipocyte hyperplasia occurs later than hypertrophy and may lead to 
more severe and irreversible metabolic consequences (Bjorntorp et al., 1974). 
Hyperplasia, also referred to as adipogenesis, results in the recruitment and 
differentiation of preadipocytes into mature adipocytes (Hausman et al., 2001). In 
vitro studies have suggested that mature adipocyte secrete factors, such as tumor 
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necrosis factor –α (TNF- α) and insulin-growth factor (IGF) that promote hyperplasia 
in a paracrine manner (Avram et al., 2007). Recent study has demonstrated that 
progenitors from the bone marrow are contributing to hyperplasia of adipocytes 
using GFP-labeled marrow cells (Crossno et al., 2006). 
 
1.2.3 Model for adipocytes differentiation and their relevance today 
Our understanding of adipogenesis comes mainly from research conducted on the 
3T3-L1 cell line, a fibroblast line derive from swiss albino mouse embryo cells 
(Green & Meuth, 1974). These preadipocytes differentiate into mature adipocytes 
under adipogenic stimuli (Student et al., 1980). Although vast amounts of 
information regarding adipogenesis are elucidated using this cell line, 3T3-L1 has its 
shortcomings. Since 3T3-L1 is already committed to the adipocytic lineage, the 
understanding of how progenitors commit to developing into adipose tissue cannot 
be studied in these cells. Due to the murine origin of 3T3-L1, there may be 
discrepancies in adipose development between murine and human model, as 
suggested by literatures (Ailhaud & Hauner, 1997; Entenmann & Hauner, 1996). For 
instance, the need for mitotic clonal expansion prior to terminal adipogenesis is 
considerably controversial. It has been reported that mitotic clonal division is 
essential for the differentiation of 3T3-L1 to adipocytes (Tang et al., 2003). 
Furthermore, there are several reports that reiterate the notion that mitotic clonal 
expansion takes precedence to differentiation (Tang et al., 2003; Reichert & Eick, 
1999; Yeh et al., 1995). Janderova et al. suggested that clonal expansion is not 
important for terminal adipogenesis to occur in humans (Janderova et al., 2003). 
Besides this, expression of Sterol Regulatory Element Binding Protein (SREBP) 
types differs between mouse and human. Murine 3T3-L1 cells express mostly 
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SREBP-1a, but in humans it is the ADD/SREBP-1c that is more involved in 
adipogenesis (Shimomura et al., 1997). Although SREBPs, unlike PPARs, are not 
master regulators of adipogenesis, different expression of SREBP types in different 
species could skew the understanding of adipogenesis in humans.  
 
Primary multipotent human cells, such as the human MSC (hMSC), can be an ideal 
model to learn about adipogenesis (Janderova et al., 2003; Nakamura et al., 2003). 
There are evidences demonstrating the ability of MSC differentiating to adipocytes 
(Baksh et al., 2003; Deans & Moseley, 2000; Pittenger et al., 1999) and contributing 
to hyperplasia of adipose tissue (Otto & Lane, 2005). Furthermore, the multipotency 
of MSC imply that these cells are prior to commitment to adipogenesis, thus can be 
used as a model for the discovery of early genes/factors that are necessary for 
commitment to adipogenesis, which remains elusive at the moment. 
 
1.2.4 Events involved in adipogenesis 
1.2.4.1 General overview of adipocyte development programme 
Much of our understanding on adipogenesis is based on 3T3-L1. Although using a 
human model, such as hMSC, may be more appropriate, the ability of MSC to 
differentiate down the adipogenic lineage is demonstrated by Pittenger et al. in 1999. 
Due to its recent introduction, insufficient knowledge on their complex biological 
system and difficulty in isolating homogenous population of MSC, MSC is not 
extensively used to study adipogenesis. Thus, subsequent description on 
adipogenesis revolves round 3T3-L1. In an in vitro system, adipogenesis is initiated 
through the exposure of confluent 3T3-L1 cultures to adipogenic cocktail containing 
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isobutylmethylxanthine (IBMX) (a cAMP elevating agent), dexamethasone (Dex) (a 
glucocorticoid hormone) and insulin (Rosen et al., 2000; Lane et al., 1999; 
Darlington et al., 1998). There are four major events governing adipocyte 
differentiation – commitment, growth arrest, mitotic clonal expansion, terminal 
differentiation.  
 
Commitment is the process by which stem cells from the vascular stroma respond to 
signals to undergo determination to the adipocytic lineage. It has been proposed that 
factors secreted by mature adipocytes signal the recruitment of cells to undergo 
adipogenesis (Marques et al., 1998; Considine et al., 1996; Lau et al., 1990). Wnt 
signaling regulates bone mass through its ability to promote osteogenesis and inhibit 
adipogenesis (Bennett et al., 2005). In addition, Wnt-10b is highly expressed in 
preadipocytes and is decreased upon differentiation (Ross et al., 2000). This implies 
that Wnt signaling may be involved in the early phase of adipogenesis (Ross et al., 
2000). Nevertheless, there is little information on the commitment process of 
adipogenesis and adipocyte-specific commitment factors remain to be discovered.  
 
Growth arrest occurs twice throughout the adipocyte development process and is 
brought about by contact inhibition (Fajas, 2003). Once before mitotic clonal 
expansion, while the other occurs prior to terminal differentiation (Scott et al., 1982). 
Literature has illustrated that there is significant increase in cyclin-dependent kinase 
inhibitors (CKI), p21 and p27, during the first mitotic arrest. Similarly, p18, a type of 
CKI, is elevated greatly at the second growth arrest (Morrison & Farmer, 1999). The 
same report documents the role of PPARγ in regulating the expression of CKI, thus 
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implying the relationship between mitotic arrest and differentiation (Morrison & 
Farmer, 1999).  
 
Upon receiving appropriate combination of mitogenic and adipogenic signals, the 
cells synchronously undergo multiple rounds of DNA replication and cell doubling 
(i.e. mitotic clonal expansion). It is believed that during DNA replication, the 
changes made to chromatin structure allow for easy access of transcription factors to 
regions of their binding sites. This in turns enable the upregulation of 834 genes and 
downregulation of 877 genes necessary for adipogenesis, thus resulting in the 
adipogenic phenotype (Lefterova et al., 2008; MacDougald & Lane, 1995). Although 
several reports reiterate the notion that mitotic clonal expansion takes precedence to 
differentiation (Tang et al., 2003; Reichert & Eick, 1999; Yeh et al., 1995), there are 
some that illustrate the non-essentiality of clonal expansion (Liu et al., 2002; Qiu et 
al., 2001; Entenmann & Hauner, 1996). Such anomaly may be the result of cells 
being initiated for differentiation at a phase beyond mitotic division (Fajas, 2003; 
Gregoire et al., 1998).  
 
Following clonal expansion, cells undergo a second growth arrest, termed GD (Scott 
et al., 1982). This marks the point of no return where cells are committed and 
determined to undergo adipogenesis (Otto & Lane, 2005).  
 
1.2.4.2 Transcriptional control 
Adipocyte differentiation involves tightly regulated gene expression events. In order 
to combat diseases that are related to adipogenesis (e.g. obesity), understanding the 
underlying transcriptional control is of utmost importance. The predominant players 
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are the peroxisome proliferator-activated receptors (PPAR), followed by the CCAAT 
enhancer binding proteins (C/EBP), then the sterol regulatory element binding 
proteins (SREBP). Other transcriptional factors will not be discussed.  
  
Peroxisome Proliferator-Activated Receptors (PPAR) 
Peroxisome Proliferator-Activated Receptors (PPARs) belong to the superfamily of 
the steroid/thyroid nuclear hormone receptor (Mangelsdorf et al., 1995). PPARs form 
heterodimers with Retinoid X Receptor (RXR) (Tontonoz et al., 1994) and in turn 
bind to a response element that regulates transcriptional activities pertaining to lipid 
metabolism, anti-inflammatory response, atherosclerosis development and 
progression (Michalik & Wahi, 1999). Presently, three PPAR family members have 
been identified: PPARα, PPARβ (also known as PPARδ) and PPARγ (Schoonjans et 
al., 1996; Dreyer et al., 1992). 
 
PPARα is mostly expressed in brown adipose tissue, liver, kidney, duodenum, heart 
and skeletal muscle (Braissant et al., 1996). It is responsible for fatty acid catabolism 
through regulating the production of acyl-coenzyme A oxidase, carnitine palmitoyl 
transferase and microsomal ω-hydroxylase (CYP4A6) (Kroetz et al., 1998; Mascaro 
et al., 1998). 
 
Relatively little is known about PPARβ/δ despite its ubiquitous expression in almost 
all tissues, except adipose tissue, and at a higher amount than PPARα and PPARγ 
(Braissant et al., 1996). Nevertheless, stimulated PPARβ is involved in embryo 
implantation, myelination, lipid metabolism and adiposity (Barak et al., 2002; Peters 
et al., 2000).  
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PPARγ is predominantly found in adipose tissue, but is also expressed in monocytes, 
macrophages, smooth muscle cells and endothelium (Wang et al., 2002). There are 
four mRNA isoforms (PPARγ1, 2, 3 and 4) created by alternative promoter usage 
and alternative splicing at the 5’ end of the gene. However, only PPARγ1 and 2 can 
be expressed as proteins (Fajas et al., 1997).  PPARγ1 is expressed at low levels in 
many cell types including adipocytes (Shockley et al., 2007; Fajas et al., 1997), 
while PPARγ2 is highly and exclusively expressed in adipose tissue (Tontonoz et al., 
1994; Braissant et al., 1996). The additional 30 residues in PPARγ2 may have 
assisted in the transcription activation function, thus increasing the expression of 
adipogenic genes by 5 to 10 folds (Werman et al., 1997; Zhu et al., 1995).  
 
Through gain and loss-of-function experiments, reports have illustrated the 
importance of PPARγ2 in adipogenesis. For instance, when PPARγ is expressed in 
non-adipogenic, fibroblastic cells or myoblastic cells co-expressing C/EBPα, high-
affinity selective PPARγ agonists, such as thiazolidinediones (TZDs) are able to 
result in strong adipogenic response in these cells (Hu et al., 1995; Sandouk et al., 
1993; Kletzien et al., 1992). In addition, through the use of zinc finger repressor 
proteins (ZFPs), such as ZFP54, PPARγ knockdowns are generated. Re-expression 
of PPARγ2, but not PPARγ1, reactivates adipogenesis in these knockdown cells (Ren 
et al., 2002). Other than genetic studies, the use of pharmacological inhibitors also 







 CCAAT Enhancer Binding Protein (C/EBP) 
CCAAT enhancer binding proteins (C/EBP) belong to the basic leucine zipper 
(bZIP) family of transcription factors. They contain a highly conserved domain at the 
C-terminus which is responsible for the dimerisation of proteins and binding to 
DNA. They act as either homo- or hetero-dimers with other family members 
(Lekstrom-Himes & Xanthopoulos, 1998). Their distribution is not only limited to 
the adipose tissue (Lekstrom-Himes & Xanthopoulos, 1998), but also to tissues that 
metabolize lipid and cholesterol-related compounds, such as the liver (Gregoire et 
al., 1998). There are a total of six members, namely C/EBPα, C/EBPβ, C/EBPδ, 
C/EBPγ, C/EBPε and C/EBPζ (Ron & Habener, 1992; Cao et al., 1991; Williams et 
al., 1991; Akira et al., 1990; Change et al., 1990; Descombes et al., 1990; Poli et al., 
1990; Roman et al., 1990). They all share substantial sequence homology in the C-
terminal 55-65 amino acid residues, which contain the bZIP domain (Hurst, 1995). 
Cellular differentiation, control of metabolism, inflammation and cellular 
proliferation are some of C/EBP functions. Adipose tissue expresses C/EBPα, 
C/EBPβ, C/EBPδ and C/EBPζ.  
 
C/EBPα comprises of three isoforms of sizes 30, 40 and 42kDa (Lin et al., 1993). 
These are generated due to the presence of multiple in-frame AUG start sites. The 
42kDa protein is the most potent inducer of adipogenesis and mitotic blocker. 
Ectopic expression of C/EBPα and C/EBPβ in 3T3-L1 cells results in adipogenesis in 
the absence of adipogenic hormones (Freytag et al., 1994; Lin et al., 1994). On the 
other hand, expression of antisense C/EBPα RNA in 3T3-L1 cells inhibits 
adipogenesis (Lin & Lane, 1992). C/EBPα-deficient mice display dramatically 
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reduced adipose tissue levels (Wang et al., 1995). These evidences address the ability 
of C/EBPα to engage in adipogenesis. 
 
Similarly, C/EBPβ also consists of three isoforms generated from alternative 
translation via multiple in-frame AUG start sites (Lin et al., 1993). Ectopic 
expression of C/EBPβ in 3T3-L1 preadipocytes is sufficient to bring about 
adipogenesis in the absence of hormone inducers (Yeh et al., 1995). When similar 
experiment is done in NIH 3T3 fibroblasts, adipogenesis also prevails, however, in 
the presence of adipogenic cocktail (Wu et al., 1995).  
 
On the other hand, no adipogenesis results when C/EBPδ is overexpressed in 3T3 L1 
and NIH 3T3 fibroblasts in the absence and presence of hormonal inducers 
respectively (Wu et al., 1995; Yeh et al., 1995). Literatures point towards C/EBPβ 
playing a larger and more important role in adipogenesis than C/EBPδ. Nonetheless, 
in the presence of adipogenic inducers, overexpression of C/EBPδ in 3T3 L1 
expedites adipogenesis (Frevtag et al., 1994; Lin & Lane, 1994). This is due to 
C/EBPβ preferentially forming heterodimers with C/EBPδ to result in greater 
transcriptional activity, despite the ability of C/EBPβ to homodimerise (Lane et al., 
1999; Cao et al., 1991; Christy et al., 1991). When both C/EBPβ and C/EBPδ are 
deficient in embryonic fibroblasts, adipogenesis fails to initiate in the presence of 
hormonal stimulus (Tanaka et al., 1997). This implies the importance of both 
transcription factors for adipogenesis. 
 
C/EBPζ, also known as C/EBP homologous protein-10 (CHOP-10), possesses 
sequence similarity with the other C/EBPs in the DNA binding and dimerisation 
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domain. However, its basic region is different from that with other C/EBPs. It does 
not form homodimers; rather it avidly forms heterodimers with other C/EBPs and it 
lacks the ability to bind to classical C/EBP-binding DNA elements (Ron & Habener, 
1992). It is absent under normal conditions and only synthesized when the cells are 
under cellular stress (e.g. glucose deprivation of cells). Ectopic expression of C/EBPζ 
in 3T3 L1 cells inhibits adipogenesis by interfering with C/EBPα and C/EBPβ 
expression and function (Tang et al., 2000; Batchvarova et al., 1995). C/EBPζ 
deficient mice display greater adiposity than the control mice (Ariyama et al., 2007). 
Thus, this implies the negative role C/EBPζ plays in regulating adipogenesis.  
 
Sterol Regulatory Element Binding Protein (SREBP) 
This group of proteins belongs to the basic helix-loop-helix-leucine zipper 
transcription factor family that regulates the transcription of genes essential to 
cholesterol and fatty acid metabolism (Horton et al., 2002). The identified members 
are SREBP-1a, SREBP-1c and SREBP-2. Adipocyte and differentiation-dependent 
factor 1 (ADD1), found in mice, is homologous to SREBP-1c found in humans 
(Tontonoz et al., 1993). SREBP-1a and SREBP-1c are derived from the alternative 
splicing of the same gene, while SREBP-2 is transcribed from a different gene (Hua 
et al., 1995). SREBPs are expressed as membrane-bound precursor protein in the 
endoplasmic reticulum (ER). Upon proteolytic cleavage, various SREBPs are 
released and subsequently translocate into the nucleus to bind to sterol response 
element and bring about the expression of target genes (Horton et al., 2002). SREBP-
1a is a strong activator of all SREBPs. SREBP-1c expresses genes related to the fatty 
acid metabolism and TAG synthesis via binding to E-box motif (CANNTG) instead 
of binding to the sterol response element (Kim & Spiegelman, 1996; Kim et al., 
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1995). SREBP-2 enhances cholesterol synthesis. More emphasis will be placed on 
SREBP-1c due to its homology to ADD1 and its importance in adipogenic 
differentiation. 
 
Overexpression of SREBP-1c induces adipogenesis in NIH 3T3 fibroblasts in the 
presence of PPARγ activators (Kim & Spiegelman, 1996).  Despite this, SREBP-1c 
knockout mice exhibit normal adipose depot (Shimano et al., 1997). The authors 
speculate that this may be due to the compensatory effects of SREBP-2, though 
present at low amounts. Formulation of knockout mice that lack both SREBP-1c and 
SREBP-2 can be useful for the study of this phenomenon. Nevertheless, evidences 
imply the importance of SREBP-1c during adipogenesis, especially during the initial 
phase of differentiation. 
 
1.2.4.3 Adipogenic transcriptional cascade 
An overview of the adipogenic transcriptional cascade based on findings using 3T3 
L1 is presented in Figure 1-2. To reiterate, the adipogenic cocktail contains insulin, 
IBMX and Dex. IBMX (a cAMP elevating agent) and insulin activate cAMP 
response element binding protein (CREB) (Klemm et al., 1998).  In turn, 
phosphorylated CREB activates C/EBPβ (Zhang et al., 2004a; Niehof et al., 1997). 
Early in differentiation, C/EBPβ expression in preadipocytes increases transiently. 
By late differentiation, its expression level decreases by 50% (Gregoire et al., 1998). 
Since mitotic clonal expansion is necessary during the early phase of adipogenesis 
and C/EBPβ is endogenously expressed during the same period of time, there is 
likelihood that C/EBPβ plays a role in mitotic expansion. There is evidence that 
C/EBPβ (-/-) mouse embryonic fibroblasts cannot undergo mitosis (Tang et al., 
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2003), thus implying the function of C/EBPβ in mitotic division and promoting 
proliferation. Phosphorylation of C/EBPβ activates its DNA binding function, which 
is quintessential in mitotic clonal expansion (Tang et al., 2005). However, this 
mechanism is still not well understood.  
 
Although C/EBPβ has the ability to homodimerise, heterodimerisation with C/EBPδ 
results in greater transcriptional activity (Lane et al., 1999; Cao et al., 1991; Christy 
et al., 1991). C/EBPδ is expressed in preadipocytes. Similar to C/EBPβ, its level 
increases transiently in early differentiation. However, by late differentiation, its 
level drops to almost undetectable range (Gregoire et al., 1998). Hence, like C/EBPβ, 
C/EBPδ may also be responsible for the clonal expansion prior to terminal 
differentiation. Since glucocorticoid has been shown to increase the expression of 
C/EBPδ (Cao et al., 1991), Dex, a synthetic glucocorticoid that is used during the 
adipogenic process, is responsible for the increase in C/EBPδ.  
 
Endogenous expression of C/EBPβ and C/EBPδ precedes PPARγ and the ectopic 
expression of C/EBPβ and C/EBPδ in NIH 3T3 fibroblasts leads to expression of 
PPARγ (Wu et al., 1996). Heterodimer C/EBPβ -C/EBPδ in turn bring about the 
expression of PPARγ. The resultant PPARγ heterodimerises with RXR and is the 
predominant factor that promote adipogenesis through the expression of hundreds of 
genes responsible for the elucidation of the adipocyte phenotype (Farmer 2005; 





C/EBPα is anti-mitotic (Umek et al., 1991) and its expression does not increase until 
the end of clonal expansion (Lekstrom-Himes & Xanthopoulos, 1998; Hendricks & 
Darlington, 1995). The expression of C/EBPα occurs prior to the expression of most 
adipocyte-specific genes (e.g. fatty acid binding protein (aP2), stearoyl-CoA 
desaturase-1 (SCD1), insulin-responsive glucose transporter (GLUT4), phosphoenol-
pyruvate carboxykinase (PEPCK), leptin and insulin receptors). Findings have shown 
that expression of C/EBPα is low in preadipocytes (Cao et al., 1991) and MSC 
(unpublished data), but high in terminally differentiated cells (Antonson & 
Xanthopoulos, 1995). Therefore, this suggests the involvement of C/EBPα in the 
termination of mitotic clonal expansion and its role as an initiator of terminal 
differentiation. In 3T3-L1 preadipocytes, the transcription factor, Sp1, represses the 
C/EBPα promoter. When cAMP levels rise (due to the presence of IBMX), Sp1 
expression is transiently down-regulated and allows C/EBPα activating transcription 
factors (i.e. C/EBPβ and C/EBPδ) to transactivate C/EBPα (Tang et al., 1999). 
Subsequently, the synergistic actions of PPARγ and C/EBPα result in adipogenic 
gene expression. It is likely that binding sites for C/EBP proteins and PPAR-RXR 
complex exist upstream of adipogenic genes. Recently, Lefterova and colleagues 
demonstrate the colocalisation of C/EBPα at more than 90% of PPARγ-binding sites 
using chromatic immunoprecipitation and that the absence of both transcription 
factors leads to decrease of common target genes (Lefterova et al., 2008). Hence, this 
further substantiates the notion that PPARγ and C/EBPα act in a concerted manner to 
bring about adipogenesis. 
 
In order to maintain the adipogenic process, C/EBPα has the ability to autoregulate 
its activation in a species-specific manner, through interaction with a site present in 
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its proximal promoter region (Timchenk et al., 1995). Besides this, the presence of a 
positive feedback loop between PPARγ and C/EBPα mutually reinforces the 
expression of PPARγ and C/EBPα, thereby sustaining the adipogenic phenotype.  
 
In some of the genetic studies, expression level of C/EBPα and PPARγ remain 
normal despite deficiency in C/EBPβ and C/EBPδ in mice (Tanaka et al., 1997). This 
implies that there are other factors regulating the expression of these transcription 
factors, such as SREBP-1c. SREBP-1c increases during the first twenty-four hours of 
adipogenic induction (Kim & Spiegelman, 1996). Due to the ability of SREBP-1c to 
bind to the E-box motif present in the PPARγ promoter, transcriptional activation of 
PPARγ results (Fajas et al., 1999). The activated PPARγ in turn induce the 
expression of C/EBPα and elucidate the expression of adipogenic genes, thus the 
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1.3.1  Definitions 
Lipids are “hydrophobic or amphiphatic small molecules that may originate entirely 
or in part by carbanion-based condensations of thioesters and/or carbocation-based 
condensation of isoprene units” (Fahy et al., 2005).  
 
1.3.2 Lipid classifications 
Lipids can be categorized into groups annotated by their chemically functional 
backbone. Glycerolipids and glycerophospholipids, herein referred to as 





- Glycerolipids: TAG, DAG, MAG
- Sterol esters
Membrane 
(e.g. Plasma membrane, LD membrane, 
mitochondria membrane, etc.)
- Phospholipids: PC, PE, PI, PS, PG, PA
- Sterol
- Sphingolipids  
Figure  1-3: Composition of lipids in an adipocyte. 
TAG: triacylglycerols; DAG: diacylglycerols; MAG: monoacylglycerols 
PC: phosphatidylcholine; PE: phosphatidylethanolamine; PI: phosphatidylinositol; PS: 
phosphatidylserine; PG: phosphatidylglycerol; PA: phosphatidic acid 
(Modified from http://i239.photobucket.com/albums/ff20/michaelwong75/fatcell.jpg) 
 
Different parts of a cell are composed of different classes of lipids (Figure 1-3). Lipid 
droplet consists of a core of neutral lipids, such as triacylglycerols (TAG) and sterol 
esters, surrounded by a monolayer of phospholipids and associated proteins (Martin 
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& Parton, 2005). Constituents of lipid membranes are made up of mainly the 
phospholipids, sterols, such as cholesterol, and sphingolipids.  
 
Phosphatidylcholine (PC) 
More than 50% of total phospholipids in the eukaryotic membrane belong to the 
class of phosphatidylcholine (PC) (Van meer et al., 2008; Kent, 2005). Due to the 
presence of one cis-unsaturated fatty acyl chain at either the sn-1 or sn-2 positions, it 
allows PC to be liquid at room temperature. With the asymmetrical distribution of 
phospholipids in the plasma membrane, PC occupies a higher proportion on the outer 
leaflet on the lipid bilayer. In addition, it tends to exist in the diacyl form, with a 
small group of them in the alkylacyl and alkenylacyl forms. These alkylacyl and 
alkenylacyl forms will be explained in greater detail in the subsequent section of 
Ether lipids and plasmalogens. PC is generally known for its structural function. 
Besides this, it also acts as a component of pulmonary surfactant and is involved in 
signal transduction (McDermott et al., 2004; Exton, 1994).  
 
 Phosphatidylethanolamine (PE) 
This is the second most abundant phospholipids, after PC. It constitutes 20-50% of 
total phospholipids in the eukaryotic system (Vance, 2008). A large proportion 
resides in the brain (Vance, 2008). Like the PC, it also exists in diacyl, alkyacyl and 
alkenylacyl forms. Similar to all other phospholipids, it also performs structural 
functions. It is the presence of both PC and PE that provides curvature stress on the 
membrane, which assists fission, fusion and budding (Marsh, 2007; Dowhan & 
Bogdanov, 2002). Furthermore, PE also participates in the disassembly of the 
contractile ring during cytokinesis of mammalian cells (Emoto et al., 1997) and is 
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involved in the hepatic lipoprotein secretion (Agren et al., 2005; Hamilton & 
Fielding, 1989). 
 
 Phosphatidylserine (PS) 
Phosphatidylserine comprises about 10-20% of all phospholipids in the plasma 
membrane and the endoplasmic reticulum. PS is located entirely in the inner leaflet 
of the plasma membrane of cells (Vance, 2008) and is a precursor to the biosynthesis 
of PE. During apoptosis, PS moves from the inner leaflet to the outer leaflet of the 
cell. The presence of PS on the surface of the cell is recognized by macrophages and 
related scavenger cells, thereby bringing about the removal of apoptotic cells. Based 
on this mechanism, PS can be used as an indicator for the clearance of apoptotic cells 
(Balasubramanian et al., 2007; Fadok et al., 2001; Fadok et al., 1992). In addition, 
PS also plays a role in the blood clotting process (Zwaal et al., 2004; Schroit & 
Zwaal, 1991; Bevers et al., 1982). The expression of PS on the surface of activated 
platelets interacts with factor VII-a tissue factor complex. This in turn activates the 
proteolytic activity of the protein, thus commencing the blood clotting cascade. PS 
also acts as co-factor for many signalling proteins, such as the protein kinase C 
(Bittova et al., 2001; Nishizuka, 1992) and neutral sphingomyelinase (Tomiuk et al., 
2000).  
 Phosphatidylinositol (PI) 
Phosphatidylinositol (PI) constitutes about 10% of the cellullar lipid repertoire 
(Pendaries et al., 2003). It is a primary source for arachidonic acid, which is 
esterified at the sn-2 position. With arachidonic acid being a precursor to eicosanoid 
production, PI is intertwined into the eicosanoid pathway. Many of the inositol 
derivatives, such as the phosphoinositides (PIPs) and inositol polyphosphates (IPs), 
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are synthesized from PI. The function of PI and its metabolites include the glycolipid 
anchoring of proteins (Shields & Arvan, 1999), signal transduction (Odom et al., 
2001; Carman & Henry, 1999; Henry & Patton-Vogt, 1998; Greenberg & Lopes, 
1996), exportation of mRNA from the nucleus (Odom et al., 2000; Saiardi et al., 
2000; Shears, 1996) and vesicle trafficking (Martin, 2001; Czech, 2000). 
 
 Phosphatidylglycerol (PG) 
Although PG is ubiquitous in all organisms, it is present at minute amounts of about 
1-2%. Despite the rarity of PG, it constitutes almost up to 5% of total phospholipid in 
lung surfactant (Harwood, 1987). It is highly essential for the normal functioning of 
the lungs (Poelma et al., 2005). Besides its residence in lung surfactant, it is also 
found in mitochondria (Dowan, 1997). Its exact role in mitochondria remains 
elusive.  
 
 Phosphatidic Acid (PA) 
PA is the simplest phospholipid in terms of structure and plays a crucial role in 
glycerolipid and phospholipid biosynthesis. Besides this, it regulates cell growth and 
proliferation through its role as a mitogenic activator of the mTOR signalling 
pathway (Chen, 2004; Foster & Xu, 2003). Also, it engages in vesicle budding at the 
Golgi, excocytosis and plasma membrane endocytosis (Jenkins & Frohman, 2005). 
There is evidence to show that PA has the secretory function. Huang et al. illustrated 
that phospholipase D1 (PLD1)-produced PA that is present on the granule 
membrane, possesses the ability to secrete insulin from pancreatic β cells (Huang et 
al., 2005). Furthermore, PA can bind to p47 component of NADPH oxidase 
complex, which in turn produces surperoxides and results in respiratory burst (Palicz 
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et al., 2001). Lastly, PA modulates cytoskeletal rearrangement. Some literature 
suggested that PA binds to actin fibers directly to bring about actin reorganization 
(Su et al., 2006; Komati et al., 2005; O’Luanaigh et al., 2002; Kam & Exton, 2001; 









Table 1-1: Structures of phospholipids. 
 (Modified from http://www.lipidlibrary.co.uk) 
 
Ether lipids and plasmalogens  
Ether lipids are lipids with ether-linked alkyl chain at the sn-1 position instead of the 
usual ester-linked fatty acid (Figure 1-5). Plasmalogens are a subset of ether lipids. 
They contain a cis bond on the alkyl chain adjacent to the ether bond, forming a 
“vinyl-ether linkage”. Plasmalogens were first identified by Feulgen and Voit in 
1924 (reviewed in Nagan & Zoeller, 2001). Later, scientists realised there are more 
plasmalogens than there are ether-linked phospholipids. PC and PE make up the 
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majority of plasmologens and ether-linked lipids. About 70% of plasmalogens 
possess an ethanolamine headgroup (Horrocks et al., 1982). Nevertheless, ether-
linked PI and PS are also present in eukaryotic cells, but at much lesser extent (about 
0.2% of total phospholipid mass) (Nagan & Zoeller, 2001). Plasmalogens function as 
a reservoir for polyunsaturated fatty acids (Tamby et al., 1996; MacDonald & 
Sprecher, 1991; Akoh & Chapkin, 1990; Ford & Gross, 1989; Chilton & Murphy, 
1986; Sugiura et al., 1987; Blank et al., 1973). They can also act as antioxidants. 
Studies have shown the vulnerability of the vinyl-ether linkage in plasmalogen to 
reactive oxygen species (ROS) (Hahnel et al., 1999; Zoeller et al., 1999 ; Hagar et 
al., 1996; Jurgens et al., 1995; Engelmann et al., 1994; Hoefler et al., 1991; Gatt & 
Osmundsen, 1988; Morand et al., 1988; Zoeller et al.,1988). When ROS 
preferentially attack the unique linkage, this spares the neighbouring molecules from 
oxidative damage, thus reducing the chance of oxidative degradation on these 
compounds. Lastly, plasmalogens are involved in membrane biogenesis and fusion. 
Gremo and colleagues have illustrated the rapid vesicular events undergone by 









Figure  1-4: Structure of ether lipid and plasmalogen – using PE as an example. 
 (Adapted from Nagan & Zoeller, 2001) 
 
 
1.3.3 Functional properties of lipids 
The classical view of lipids is that they serve as energy storage in the form of lipid 
droplets. Besides being an efficient storage of energy reserves, lipid droplets also 
provide a source of fatty acids and sterol components for membrane biogenesis (Van 
meer et al., 2008), a function that has been conserved from prokaryotes to eukaryotes 
(Waltermann & Steinbuchel, 2005; Murphy, 2001).  
 
In addition to energy storage, lipids are also constituents of lipid membranes. Polar 
lipids, which are amphiphatic, allow hydrophobic regions to associate themselves 
together and hydrophilic moieties to interact with each other and water. This offers 
the physical basis of lipid membrane formation. Consequently, presence of lipid 
membranes enable the segregation of internal components from the external 
environment (Van meer et al., 2008), compartmentalizing the cell. Different 
chemical reactions can occur in their own niche, thereby increasing their efficiency. 
32 
 
Furthermore, with the formation of the membranes, fission, fusion and budding will 
be possible and are necessary for cell division and trafficking.  
 
Lipids have also acquired the ability to act as signalling molecules that lead to 
various cellular functions, such as cell growth, death and migration. Sphingolipids 
possess an emerging role in cell signalling, growth and death (Gomez-Munoz, 2006; 
Merril et al., 1997; Spiegel & Merrill, 1996). Degradation of lipids, such as the 
phosphatidylinositol-4,5-bisphosphate, yields an array of molecules that serve as 
signalling molecules (Wenk, 2005). Some of these molecules can initiate signaling 
cascades that result in the release of calcium from the endoplasmic reticulum 
(Berridge, 1987, 1984). Also, oxidized products of cholesterol, such as 22 (R)-
hydroxycholesterol (HC), 24 (S)-HC, 27-HC and 24 (S), 25-HC, act as ligands for 
liver X receptors α and β. At physiological concentrations, they can prevent 
development of atherosclerosis in animal models (Tontonoz & Mangelsdorf, 2003; 
Tangirala et al., 2002).  
 
Lipids also play vital roles in inflammatory, algesic and pyrogenic cascades. The 
release of arachidonic acid from glycerophospholipids by phospholipase action leads 
to the synthesis of eicosanoids. Its derivatives have been well studied for their 
involvement in inflammatory process (Balazy, 2004). Funk et al., in their review on 
prostaglandins and leukotrienes, have illustrated the actions of prostaglandins in 
eliciting inflammatory, algesic and pyrogenic response, depending on the location of 
action; leukotrienes in causing allergic inflammation (Funk et al., 2001).  
Lastly, lipids also have immunomodulatory function. In terms of pathogen 
recognition, some Toll-like receptors (TLR) are able to recognize lipid compounds 
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(Akira & Takeda, 2004; Poltorak et al., 1998). For instance, TLR-2 is able to 
recognize glycoinositolphospholipids and glycolipids (Coelho et al., 2002; Opitz et 
al., 2001). Moreover, various classes of lipid have been discovered to be able to bind 
to CD1 receptors and evoke a T-cell response (Sieling et al., 1995; Porcelli et al., 
1989). Most amazingly, some bacteria have perfected the ability to evade host 
immune system through the shedding of bacterial lipids, thereby invading and 







1.4 Relationship between lipids, MSC and adipogenesis 
1.4.1 Effects of lipids on adipogenesis 
It is only recently that there is emerging literatures on how lipids affect adipogenesis 
in MSC. Most works on lipids modulating the adipogenic pathway are carried out in 
3T3-L1 cells in vitro. Despite this, inference from 3T3-L1 works can provide insight 
on types of lipids that can regulate the development of adipocytes in MSC. This 
section unfolds the various classes of lipids having an effect on adipogenesis. 
 
Different forms of sterols have varying effects on adipogenesis. Oxysterols have 
been shown to inhibit adipogenesis in MSC. Exogenous addition of 20(S)-
hydroxycholesterol (20S) to mouse MSC inhibits troglitazone-induced adipocyte 
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formation (Kim et al., 2007). In addition, 22 (R)-hydroxycholesterol (22R), 22 (S)-
hydroxycholesterol (22S) and 20S also inhibit troglitazone-induced adipogenesis in 
the following order of 20S ≥ 22S > 22R in mouse MSC (Kha et al., 2004). It has 
recently been reviewed that oxysterols act as novel activators of the hedgehog 
signalling pathway, thereby inhibiting adipogenesis and promoting osteogenesis 
(Eaton, 2008; Dwyer et al., 2007). On the other hand, supplementation of another 
form of sterol, 17-β estradiol, enhances adipogenesis in human MSC by acting 
through estrogen receptor (ER) α (Hong et al., 2006).  
 
15-deoxy-∆12, 14-prostaglandin J2 (15dPGJ2) promotes adipogenesis (Mazid et al., 
2006). Based on their in-house enzyme-linked immunosorbent assay (ELISA), they 
discovered that adipocytes differentiated from 3T3-L1 secrete 15dPGJ2. 
Furthermore, the accumulation of lipid droplets in the adipocytes correlates with the 
increasing amounts of secreted 15dPGJ2. When cycoloxygenase inhibitors (aspirin 
and indomethacine) are added, no formation of lipid droplets is observed. This 
phenomenon is reversed when prostaglandin D2 (precursor of 15dPGJ2) is added 
exogenously. They propose that this may be due to 15dPGJ2’s PPARγ agonist status 
that allows it to bind to PPARγ and results in the expression of adipogenic genes, 
thus adipogenesis prevails. Troglitazone, a well-known specific PPARγ agonist, also 
exhibits similar effect when used under the same conditions.  
 
Conversely, another member of the prostaglandin family, prostaglandin 2α (PGF2α), 
inhibits adipogenesis in 3T3-L1 during early differentiation (Liu & Clipstone, 2007). 
PGF2α does not affect the expression and activity of C/EBPβ, thus implying that it 
probably acts after the first mitotic clonal expansion in the early phase of 
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adipogenesis. The paper suggests that PGF2α may have acted through the 
calcineurin-dependent mechanism that inhibits the expression of essential 
transcription factors, C/EBPα and PPARγ, thus preventing adipogenesis (Liu & 
Clipstone, 2007).  
 
Fatty acids (FA) can be pro- or anti-adipogenic depending on their carbon chain 
lengths, degree of unsaturation and location of double bonds. Medium-chain length 
FA, such as octanoic acid (FA 8:0) and decanoic acid (FA 10:0), increase lipid 
accumulation in 3T3-L1, with decanoic acid (FA 10:0) being a stronger inducer 
(Yang et al., 2008). On the other hand, ω-3 polyunsaturated FA, such as 
docosahexaenoic acid (DHA; FA 22:6) and eicosapentaenoic acid (EPA; FA 20:5), 
inhibits adipogenesis through suppression of adipogenic gene expression in 3T3-L1 
(Lee et al., 2008; Kim et al., 2006; Madsen et al., 2005). Conversely, ω-6 
polyunsaturated FA, such as linoleic acid (FA 18:2), enhances lipid droplet formation 
within human preadipocytes (Madsen et al., 2005; Hutley et al., 2003). Arachidonic 
acid (FA 20:4), another ω-6 polyunsaturated FA, does not directly affect 
adipogenesis. Rather, its metabolites, prostaglandins have dual effects on 
adipogenesis (Liu & Clipstone, 2007; Mazid et al., 2006).   
 
Lastly, lysophosphatidic acid (LPA) has been demonstrated to stifle adipogenesis in 
both mouse and human preadipocytes (Simon et al., 2005). LPA binding to LPA1 
receptor present on preadipocytes reduces the expression and activity of PPARγ, 
preventing the ensuing expression of adipogenic genes, such as fatty acid binding 
protein (aP2), stearoyl-CoA desaturase-1 (SCD1), insulin-responsive glucose 
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transporter (GLUT4), phosphoenol-pyruvate carboxykinase (PEPCK), leptin and 
insulin receptors. 
 
Although these are probable lipids that can modulate adipogenesis, they take place in 
preadipocytes, which are committed to adipogenesis. Exogenous addition of lipids to 
MSC would be interesting as this would provide some insight as to whether these 
lipids can enable commitment to adipogenesis and ultimately terminal 
differentiation. 
 
1.4.2 How MSC can contribute to obesity 
Obesity can be brought about by adipocyte hypertrophy (increase in size of 
adipocyte) followed by adipocyte hyperplasia (increase in number of adipocytes). 
The enlargement of adipocyte occurs early in obesity and levels off, while the 
increase in number of adipocytes persists throughout obesity (Bjorntorp 1974). This 
implies that once adipocytes reach its maximum size, other factors may be activated 
thus contributing further to obesity. Studies have suggested that mature adipocytes, 
as an endocrine organ, can secrete factors that signal preadipocyte proliferation and 
differentiation. For instance, conditioned media from adipocytes or hyperptrophic 
white adipose tissue result in adipogenesis of preadipocytes (Marques et al., 1998). 
In addition, mature adipocyte secretes tumor necrosis factor –α (TNF- α) and insulin-
growth factor (IGF) that can promote hyperplasia in a paracrine manner (Avram et 
al., 2007). In addition, a recent report demonstrates that progenitors of white 
adipocytes reside in the adipose vasculature. The authors propose that the adipose 
vasculature forms the niche that provides suitable signals for adipocyte development 
(Tang et al., 2008). Furthermore, there is evidence illustrating that bone-marrow 
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derived preadipocytes can migrate and contribute to fat deposits using GFP-labeled 
bone marrow cells (Crossno et al., 2006). These substantiate the notion that MSC 
and preadipocytes, under the appropriate stimuli, can differentiate and lead to 
hyperplasia of adipocytes and ultimately obesity.  
 
1.4.3  Lipidomics 
Lipidomics is a branch of metabolomics that adopts a systems-level approach in 
studying all lipids, their interacting partners and their functions within the biological 
system (Watson, 2006; Wenk, 2005). However, this alone is not enough. Through 
integration of genomics and proteomics, a more wholesome overview of how lipids 
function in a biological system can be achieved. Since genomics and proteomics data 
on MSC are already available (Jeong et al., 2007; Park et al., 2007; Lee et al., 2006; 
Silva et al., 2003), metabolomics is the remaining piece required to unlock the 
mystery of MSC. This aspect of the –omics genre provides information on the 
downstream effects of gene and protein regulation, thus presents the link to 
biological state of the system (Goodacre et al., 2004). To bring us one step closer to 
understanding the biology of MSC, we will first look at lipidomics of MSC.  
 
Lipids used to be known for their membrane forming and energy storing abilities. To 
date, they are also involved in cell signaling, inflammatory actions and 
immunomodulatory functions. With the immense combinatory structural diversity of 
lipids, improved analytical methods are required. Mass spectrometry can be the 
solution as it is acutely sensitive, efficient and of high throughput. For instance, 
crude lipid extract of biological fluid or tissue, even at minute amounts, when 
introduced into the mass spectrometer will lead to the derivation of a “fingerprint” of 
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the biological substance. By employing this method, subtle changes in the lipid 
composition of cells can be detected (Milne et al., 2006; Ivanova et al., 2004). 
 
Understanding the lipid profile and identifying the lipid changes between 
undifferentiated and differentiated MSC enables the targeting of probable lipids 
involved in adipogenesis. For instance, after determining distinct lipid changes, 
metabolic pathways related to these lipids can be recognized. Subsequently, one can 
hypothesize links between the metabolic pathway of interest and the adipogenic 
pathway and from there uncover areas where intervention may attenuate 
adipogenesis, and thus provide an alternative solution to obesity. Since there are 
evidences to show that lipids can modulate adipogenesis and MSC can play a role in 
obesity through hyperplasia, acquiring the lipid profile will take us one step closer to 
comprehending adipocyte biology and in turn able to combat obesity more 
efficiently. 
1.5 Hypothesis 
When MSC undergo adipogenesis, the resultant adipocytes possess unique lipid 
signatures/profiles different from their predecessors, which can serve as possible 
markers to distinguish the different stages of differentiation.  
 
1.6 Objectives 
1) To validate the adipogenic status of terminally differentiated MSC via 
histochemistry, real time polymerase chain reaction (PCR) and fluorescence 
activated cell sorting (FACS) 
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2) To determine phospholipid and TAG changes between MSC and MSC derived 
adipocytes using thin layer chromatography (TLC) and mass spectrometry (MS) 
approaches 




MSC cultures are expanded to the predetermined optimized passage five (P5) before 
adipogenic differentiation takes place. Adipogenic inducers, namely insulin, 
dexamethasone (Dex), indomethacine (Indo) and isobutymethylxanthine (IBMX), are 
exogenously added to cultures at optimized concentrations (refer to Materials and 
Methods – 2.1.1).  
 
Based on prior optimization work, LD starts to form after seven days of adipogenic 
induction. In order to compare between the early and late stges of differentiation, 
weekly timepoints were set up. Four timepoints are chosen during adipogenic 
differentiation protocol (day0, day7, day14 and day21) (Figure 1-6) for the 
determination of changes in cellular lipid profile. Pairwise comparisons are made 
between undifferentiated cells (UD) and differentiated cells (Adipo) at these selected 











Figure  1-5: Experimental timepoints. 
Day 0 denotes the start of adipogenic differentiation 
Day 7, 14 and 21 referred to 7, 14 and 21 days after adipogenic induction 
respectively 
 
The workflow comprises of two parts (Figure 1-7). In the first part (Part I), triplicate 
samples collected at each timepoint are subjected to two sections – validation of 
adipogenesis and characterization of lipids. In order to determine that MSC undergo 
adipogenesis, fluorescence activated cell sorting (FACS) to quantitate the extent of 
differentiation, histochemical staining of lipid droplets (LD) using Oil Red O 
solution, real time polymerase chain reaction (real time PCR) for adipogenic gene 
expression analysis and simple observation using phase contrast microscope for 
visualization of LD are performed. Various thin layer chromatography (TLC) and 
mass spectrometry (MS) techniques are employed to profile lipid changes when 
MSC differentiates into adipocytes. Mainly two TLC methods, Hexane:Diethyl 
ether:Formic acid (HEFA) and Chloroform:Methanol:Water (CMW), are adopted. 
HEFA and CMW allow for the resolution of neutral and polar lipids respectively. In 
order to dwell deeper into the changes observed from the TLC, single scan MS is 
used to obtain an unbiased lipid profile. Tandem MS and precursor ion scan (PREIS) 
elucidate the identity of lipid species, while multiple reaction monitoring (MRM) 




After analyzing the lipid profiles, certain enzymes seem to suggest their involvement in 
the lipid changes observed. The second part (Part II) of the workflow is designed as an 
attempt to explain these changes. Real time PCR is used to determine the relative gene 
expression of the enzymes of interest. However, gene expression of these enzymes does 
not translate to their phenotypic function. Immunoblotting serves as an independent assay 
to validate the gene expression analysis. Materials and methods used are discussed in 
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2 Materials and Methods 
2.1 Tissue culture 
2.1.1  Adipogenesis 
Human mesenchymal stem cells (MSC) purchased from Cambrex (East Rutherford, 
NJ) were maintained in Dulbecco’s modified Eagle’s medium (DMEM – 1000mg/ml 
glucose; Sigma-Aldrich. St Louis, MO), 10% (v/v) fetal bovine serum (FBS) (Lonza. 
Bassel, Switzerland), 2mM of L-glutamine (Gibco-Invitrogen. Carlsbad, CA), 
100units/ml of penicillin (Gibco-Invitrogen. Carlsbad, CA) and 100μg/ml of 
streptomycin (Gibco-Invitrogen. Carlsbad, CA) (maintenance media). Cells were 
passaged at 80% confluence via trypsinisation (0.125% Trypsin/Versene in 
Dulbecco’s Phosphate Buffered Saline without calcium chloride and magnesium 
chloride (DPBS)) (Sigma-Aldrich. St Louis, MO). Cells were counted via 
hemocytometer and seeded 5000 cells/cm2. For adipogenic differentiation, hMSC 
were seeded at 18000 cells/cm2. Upon reaching 100% confluence, maintenance 
media was switched to adipogenic media (maintenance media containing 4500mg/ml 
glucose, 10μg/ml Insulin (Sigma-Aldrich. St Louis, MO), 115μg/ml 3-Isobutyl-1-
methylxanthine (Sigma-Aldrich. St Louis, MO), 1μM Dexamethasone (Sigma-
Aldrich. St Louis, MO) and 20μM Indomethazine (Sigma-Aldrich. St Louis, MO) for 
the next 21 days. Media were changed twice a week. All culture incubations were 





2.2 Oil Red O staining 
Oil Red O staining was used to identify lipid droplet formation within cells. In situ, 
adherent cells were washed with DPBS (Sigma-Aldrich. St Louis, MO) and fixed in 
4% (w/v) paraformaldehyde (Sigma-Aldrich. St Louis, MO) for 1 hour at room 
temperature. The fixative was removed and cells were washed with water. The cells 
were stained with filtered 0.36% (w/v) Oil Red O solution (Sigma-Aldrich. St Louis, 
MO) in 60% (v/v) isopropanol (BDH – Merck. Whitehouse Station, NJ) for 1hour at 
room temperature. The cells were washed with 60% (v/v) isopropanol twice followed 
by 5 washes with water. Next, cells were counterstained with Mayer’s hematoxylin 
solution (Sigma-Aldrich. St Louis, MO) for 5 minutes at room temperature (RT) 
followed by 3 washes with water. Images were captured using a dissecting 
microscope (Olympus SZX12. Tokyo, Japan) in 5 random fields at the different 
magnifications. 
 
2.3 Fluorescence Activated Cell Sorting (FACS) 
To quantitate the percentage of MSC that contained lipid droplets, Nile Red staining 
of cells and flow cytometry were employed (BD FACSCalibur (Biomed Diagnostics. 
White City, OR)). Briefly, cells were harvested via trypsinisation and following 
centrifugation (400 x g, 5mins RT), cell pellet was resuspended in DPBS. However, 
for day 21 adipocyte samples, in addition to the above method, region between the 
cell pellet and floating adipocytes was also aspirated. The final cell suspension and 
samples from between the cell pellet and floating adipocytes were subsequently 
stained with 1μg/ml of Nile Red solution (Sigma-Aldrich. St Louis, MO). Excitation 
and emission at different wavelengths reflect Nile red interactions with either neutral 
or polar lipids (Greenspan & Fowler, 1985). Using FACS, cells detected on the FL2 
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channel are those containing neutral lipids. Firstly, cells were gated in a pre-
determined forward scatter (FSC) and side scatter (SSC) region. Next, cells within 
the gated region and detected on FL2 were counted and marked by marker 1 (M1). 
As a result, the number of MSC containing lipid droplets was revealed. All data in 
histograms has been gated on the same FSC and SSC region.  
 
2.4 Gene expression 
2.4.1 RNA extraction 
Cells were washed with DPBS and lysed in 1ml of TRIzol® reagent (Invitrogen. 
Carlsbad, CA). Cell lysates were incubated at room temperature (RT) for 5 minutes 
before adding 200μl of 100% chloroform and mixing well. Following 2 minutes 
incubation at room temperature, samples were centrifuged at 12000g for 15 minutes 
at 4°C. The upper aqueous phase was collected and 500μl of 100% isopropanol was 
added. The samples were incubated at -20°C for 20 minutes and the RNA pelleted 
via centrifugation (13200g for 15 minutes at 4°C). The supernatant was aspirated and 
the RNA pellet washed with 1ml of 75% (v/v) ethanol and re-pelleted (13200g for 15 
minutes at 4°C). The supernatant was aspirated and the pellet air-dried before re-
suspending in RNAse/DNAse free water, containing 1/10 (v/v) RNAseOUT 
(Invitrogen. Carlsbad, CA). Concentrations of all RNA samples were determined by 
measuring absorbance at wavelengths of 260nm and 280nm using the Spectrometer 
(NanoDrop®. Thermo Scientific. Waltham, MA). It was assumed that an absorbance 
of 1 at 260nm was equivalent to 40μg/ml RNA and 33μg/ml of oligonucleotides. The 
ratio of absorbance at these two wavelengths was used to estimate the purity of the 
RNA. To check the integrity of the RNA, electrophoresis of 1% (w/v) TAE gel (1g 
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agarose powder (Invitrogen. Carlsbad, CA) in 100ml 1X TAE (Tris base (Sigma-
Aldrich. St Louis, MO), Glacial acetic acid (BDH – Merck. Whitehouse Station, NJ) 
and 0.5M ethylenediaminetetraacetic acid (EDTA) (Sigma-Aldrich. St Louis, MO) 
pH8.0) buffer) containing 0.5 mg/ml of ethidium bromide (Sigma-Aldrich. St Louis, 
MO Aldrich) at 120V for 25 minutes was carried out. Images of the bands were 
visualized via ultraviolet light using Gel documentation system (VLChemiSmart 
3000. France).  
 
2.4.2 DNA digestion 
1μg of total RNA was treated with 1μl of RQ1 RNase-Free DNase I (Promega. 
Fitchburg, WI) and 1μl of RQ1 DNase 10X reaction buffer (Promega. Fitchburg, WI) 
and topped up with DNase/RNase free water to yield a total reaction volume of 10μl. 
After incubating at 37°C for 40 minutes, digestion was curbed using 1μl of RQ1 
DNase STOP solution (Promega. Fitchburg, WI) and incubated at 65°C for 10 
minutes. Negative control for the subsequent Polymerase Chain Reaction (PCR) was 
collected by aspirating 1μl from the above mixture and added to 19μl of 10mM Tris 
pH 8.5 (Sigma-Aldrich. St Louis, MO). The above protocol was carried out for all 
samples in duplicates.  
 
2.4.3 Reverse transcription 
To 1μg of DNA digested- total RNA , 1.5μl of 10mM dNTPs mix (Invitrogen. 
Carlsbad, CA), 1.5μl of 250ng/μl of random hexamers (Invitrogen. Carlsbad, CA) 
and 7μl of DNase/RNase Free water were added. They were then heated at 65°C for 
5 minutes, After a quick chill on ice, 6μl of 5X modified First Strand buffer 
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(Invitrogen. Carlsbad, CA), 1.5μl of 0.1M of dithiothreitol (DTT, Invitrogen. 
Carlsbad, CA), 1μl of 40units/μl of RNAseOUT and 1.5μl of SuperscriptTM III 
(Invitrogen. Carlsbad, CA) were added. The samples were incubated at 25°C for 10 
minutes, followed by 120 minutes at 50°C. Finally, reverse transcription was 
inactivated by heating at 70°C for 15 minutes. Upon completion, duplicate samples 
were pooled and diluted in 400μl of 10mM Tris pH 8.5.  
 
2.4.4 Polymerase Chain Reaction (PCR) 
Verification of DNA digestion was carried out via standard PCR using AmpliTaq 
Gold DNA polymerase (Applied Biosystems. Foster City, CA). 5μl of 10X PCR 
buffer (Applied Biosystems. Foster City, CA), 5μl of 25nM Magnesium chloride 
(Applied Biosystems. Foster City, CA), 2μl of 10mM dNTPs, 4μl of 5μM GAPDH 
primer pair (Appendix 1), 0.25μl of 5 units/μl AmpliTaq Gold DNA polymerase, 
31.75μl of DNase/RNase Free water and 2μl of template (DNase-treated RNA or 
cDNA). Thermal cycling consisted of a 10 minutes heat activation step at 95°C, 30 
cycles of denaturation at 95°C for 30 seconds, annealing at 55°C for 45 seconds and 
extension at 72°C for 30 seconds. A final 10 minutes extension time at 72°C 
concluded the PCR reaction. This was performed in a thermal cycler (Thermo 
Electron Corporation. Waltham, MA). 
 
2.4.5 Real time PCR 
2X SYBR® Green PCR master mix (Applied Biosystems. Foster City, CA) was used 
to carry out real time PCR. In short, 5μl of cDNA was added to 10μl of 2X SYBR® 
Green PCR master mix followed by 5 μl of 2μM primer pairs (100μM forward and 
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100μ M reverse, with the final amounts being diluted to 2μM). A resultant final 
reaction volume of 20μl was yielded. All reactions were performed in duplicates in 
Corbett Research Rotor GeneTM  reaction tubes (Corbett Research. Sydney, Australia).  
 
The PCR cycling parameters included an activation of 15 minutes at 95°C, followed 
by 45 cycles of denaturation of 95°C for 30 seconds, annealing at 55°C for 30 
seconds and extension at 72°C for 30 seconds. Fluorescence data was recorded at the 
end of each extension step. To conclude each run, a DNA melt profile was run from 
72°C to 95°C with a ramp of 1°C every 5 seconds. Fluorescence data was recorded 
continuously during the melt profile and allowed the identification of specific 
amplicon production or primer dimers. The second derivative analysis (d2F/dT2) of 
the melt curve showed a single peak for specific amplicons and a non-specific or 
broad peak identified PCR artefacts. A single run quantified and determined the level 
of expression of the following genes in undifferentiated and differentiated cells at 
different timepoints: 5 presumptive housekeeping genes (β-actin, GAPDH, HMBS, 
HPRT and 18s rRNA; sequence refer to Appendix 1) and 15 genes of interest 
(PPARG1, PPARG2, C/EBPα, C/EBPδ, aP2, LPL, PLA1, PLA2-G4a, PLA2-G6, 
PLB, Lipin1, Lipin2 and Lipin3, LPPa, LPPb; sequence refer to Appendix 1) 
 
CT values were imported into Microsoft Excel. The relative expression of the 5 
housekeeping genes was examined by the CT method (Vandesompele et al., 2002). 
Assuming equal amplification values, gene expression were normalized against 
every other gene. All 5 housekeeping genes were selected and their expression 
normalized by determining their geometric mean (Vandesompele et al., 2002). Gene 
expression values were normalized against this geometric mean and allowed 
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comparison between undifferentiated and differentiated cells at various timepoints. A 
2.5 fold change in expression relative to undifferentiated cells was deemed 
significant because of the acute sensitivity of real time PCR which resulted in 
frequently observed fluctuations in gene expression of up to 50% despite using 5 
housekeeping genes to normalize data.  
 
2.5 DNA quantification 
In order to normalize results obtained from mass spectrometry, total DNA was 
extracted from cells and quantitated using Pico Green (Molecular Probes P7589 
Quant-iT PicoGreen dsDNA kit. Invitrogen. Carlsbad, CA). Briefly, cells were 
scrapped in ice cold DNAse/RNAse free water (Gibco-Invitrogen. Carlsbad, CA). 
The cell lysates underwent 3 freeze/thaw cycles and later spun down at 10000rpm for 
2 minutes to pellet cell debris.  
 
In a standard 96 well flat bottom culture dish, DNA standards and samples were 
added in a final volume of 50μl. A Standard curve (in duplicate) ranging from 
2μg/ml to 0.03125 μg/ml was obtained by serial diluting lambda DNA. Samples were 
analysed in triplicate following a predetermined optimal 1:4 dilution in TE. Finally, 
PicoGreen solution was added in a 1:1 ratio to all wells, and incubated for 5 mins at 
RT in the dark. Fluorescence was read at 495/515nm using Wallac VictorTM3 
multilabel counter (Perkin Elmer. Foster City, CA). Standard curve with R2 value of 
0.99 or greater was used for the determination of DNA concentration in samples. 





2.6.1 Lipid standards 
For phospholipids analysis, the following were used as standards. Phosphatidic acid 
with C20 fatty acyl chains (diarachidonoyl PA, 40:8-PA), C14-phosphatidylserine 
(dimyristoyl PS, 28:0-PS), C14-phosphatidyglycerol (dimyristoyl PG, 28:0-PG), 
C14-phosphatdiylethanolamine (dimyristoyl PE, 28:0-PE), C14-phosphtidylcholine 
(dimyritoyl PC, 28:0-PC) were obtained from Avanti Polar Lipids (Alabaster, AL). 
Phosphatidylinositol with C8 fatty acyl chains (dioctanoyl PI, 16:0-PI) was obtained 
from Echelon Biosciences, Inc. (Salt Lake City, UT). The internal standards were 
solubilized in chloroform at a stock concentration of 10 μg/μl. 
 
2.6.2 Total lipid extraction 
Undifferentiated MSC and MSC-differentiated adipocytes were harvested at 4 
timepoints, namely day0 (point of time when MSC reached 100% confluence and 
adipogenic induction was to begin), day 7, day 14 and day 21 post-adipogenic 
induction. Modified Bligh and Dyers phospholipid extraction was carried out (Bligh 
& Dyer, 1959). Briefly, cells were washed in ice-cold DPBS. Following total 
aspiration of DPBS, cells were scraped in 400μl of ice-cold 100% methanol (Merck. 
Whitehouse Station, NJ) on a cold plate (Thermo Shandon. Pittsburgh, PA) and 
collected into eppendorf tubes. 200μl of ice-cold 100% chloroform (BDH – Merck. 
Whitehouse Station, NJ) was added to cell suspension and vortexed for 1minute 
before 10 minutes incubation on ice. Next, 300μl of 100% chloroform was added, 
followed by 450μl of MiliQ water. This was subsequently vortexed for 2 minutes and 
incubated in ice for 1 minute. The samples were centrifuged at 20000g for 5 minutes 
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at 4°C to bring about phase separation. The lower organic phase was collected and 
transferred into a clean fresh microfuge tube (Axygen. Union City, CA). Re-
extraction was performed with 600μl of 100% chloroform. Extracted lipids were 
dried down using the SpeedVac (Thermo Electron Corporation. Waltham, MA) and 
stored at -80°C. 
 
2.7 Thin Layer Chromatography (TLC) 
Two solvent systems were used to resolve polar and neutral lipids.  
For polar lipid resolution, chloroform:methanol:water (60:12:1, v/v) system was 
used. A Silica gel 60 (Merck. Whitehouse Station, NJ) TLC plate was heated at 
105°C for 15 minutes. An allowance of 1.5cm from the base, 1cm from the sides and 
2 cm from the top were determined before samples (day 0, day 21 undifferentiated 
and day 21 differentiated samples) and standards (1-Palmitoyl-2-Oleoyl-sn-Glycero-
3-Phosphoethanolamine (POPE), 1-Palmitoyl-2-Oleoyl-sn-Glycero-3-
Phosphocholine (POPC), L-a-Phosphatidylserine (PS), natural plant, soybean 
Phosphatidylinositol (PI), 1,2-Dimyristoyl-sn-Glyero-3-Phosphocholine (DMPG), 1-
Palmitoyl-2-Oleoyl-sn-Glycero-3-Phosphatidic acid (POPA) and cholesterol – 
Avanti® polar lipids, Inc. Alabaster, AL) were deposited. Each spot was 1cm apart 
and 2μg of standards were used. Each of the dried down lipids samples was 
resuspended in 200μl of chloroform:methanol (1:1, v/v), of which 50μl was 
transferred into a fresh tube and dried down via the SpeedVac. 5μl of 
chloroform:methanol (1:1, v/v) was used to solubilise the newly dried down lipids 
and spotted on to the plate. When all required standards and samples were spotted, 
the plate was left to dry before placing it in the chamber for migration. Once the 
solvent had reached the 2cm mark (from the top), the plate was removed and left to 
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dry. The migrated lipids were visualized by placing the plate in a tank saturated with 
iodine vapour.  
 
For neutral lipid resolution, hexane:diethyl ether:formic acid (45:5:1, v/v) system 
was used. The above described method was carried out except that the standards used 
were as follows cholesterol, TAG mix (consisting of glyceryl tridecanoate, glyceryl 
tridodecanoate, glyceryl trimyristate, glyceryl trioctanoate and tripalmitin purchase 
as a mixture from Sigma-Aldrich. St Louis, MO), MDT mix (consisting of 1,3-
Diolein, 1,2-Dioleoyl-rac-glycerol, Triolein and Monoolein purchased as a mixture 
from Sigma-Aldrich. St Louis, MO), C17-ceramide (Avanti® polar lipids, Inc. 
Alabaster, AL), oleic acid (Sigma-Aldrich. St Louis, MO) and 1-Palmitoyl-2-Oleoyl-
sn-Glycero-3-Phosphoethanolamine (POPE).  
 
Standard curve of each lipid class ranging from 10mg/ml to 0.3125mg/ml was 
obtained by serial diluting each of the lipid standard described above. Subsequently, 
appropriate lipid standards and their diluted counterparts were resolved in the 
appropriate systems. The resulting spots were analysed via densitometric scanning of 
iodined stained plates using the NIH ImageJ software. Standard curve with R2 value 
of 0.98 or greater was used for the determination of lipid concentration in samples. 
Average deviation of 5% or less was considered acceptable within triplicates. The 





2.8 Mass spectrometry (MS) 
2.8.1 Single scan MS 
Dried down lipid samples were resuspended in 200μl of chloroform:methanol (1:1, 
v/v). Debris were pelleted through centrifugation at 14000 g at 4°C for 10 minutes. 
100μl of sample was aspirated from the top and introduced into the Waters 
Micromass Q-Tof Micro (Waters Corp. Milford, MA) mass spectrometer, in which 
electrospray ionization mass spectrometry (ESI-MS) was to be performed. The 
samples were directly infused using a Harvard syringe pump at a flow rate of 
10μl/min. The capillary voltage and sample cone voltage were both maintained at 
3.0kV and 50V respectively, while the source temperature was kept at 80°C and the 
nano-flow gas pressure at 0.7 bar. The mass spectrum acquired was in the range of 
mass-to-charge ratio (m/z) of 400 to 1200 in the negative ion mode, with an 
acquisition time of 5 minutes and scan duration of 1 second.  
 
2.8.2 Tandem MS (MS/MS) 
To acquire the identity of individual molecular species, tandem mass spectrometry 
(MS/MS) using the Waters Micromass Q-Tof Micro (Waters Corp. Milford, MA) 
mass spectrometer was performed. Lipid samples were introduced into the machine 
in the same way as for the single scan MS, using a Harvard syringe pump at a flow 
rate of 10μl/min. Similarly, the parameters used for single scan MS were also used 
for tandem MS as well. However, unlike the single scan MS, MS/MS was carried out 
individually for each m/z value. For instance, MS/MS for m/z value X comprise of 
pre-setting the first cell with X, followed by acquiring the mass spectrum from m/z 
of 50 to X + 50 in the negative mode, with an acquisition time of 5 minutes and scan 
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duration of 1 second. A range of collision energy from 25 to 40eV is used to achieve 
desired fragmentation.  
2.8.3 Precursor Ion Scanning (PREIS) and Multiple Reaction Monitoring 
(MRM) 
The identification of lipid molecular species was carried out via precursor ion 
scanning (PREIS) and quantification by multiple reaction monitoring (MRM), with 
both using the Applied Biosystems 4000 Q-Trap mass spectrometer (Applied 
Biosystems. Foster City, CA, Foster City, CA). The HPLC system, consisting of 
Agilent 1100 Thermo Autosampler and an Agilent 1100 LC Binary Pump, was used 
to provide the mobile phase (chloroform:methanol (1:1, v/v)) and to introduce the 
samples into the machine. Flow rate differed between the modes used. In the positive 
mode, flow rate was set at 250μl/min over 1.5 minutes. In the negative mode, flow 
rate was at 200μl/min over 2 minutes. The ion spray voltage was set at -4500 V for 
the negative mode and 5500V for the positive mode.  Temperature was set at 250°C. 
Nitrogen was used as curtain gas (value of 20) and collision gas was set to high. 
These settings were applied to both PREIS and MRM. 
 
Prior to MRM, PREIS was carried out to determine the precursor ion of interest by 
allowing all ions to pass through the first quadrupole, Q1, and into the collision cell, 
Q2, where they underwent collision-induced dissociation (CID). In the third 
quadrupole, Q3, structure specific product ion characteristic was set in accordance to 
Appendix 2.  
 
In MRM, the first quadrupole, Q1, was set to allow precursor ion of interest to pass 
through and enter the collision cell, Q2, where they were subjected to CID. In the 
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third quadrupole, Q3, structure specific product ion characteristic of the lipid of 
interest were set to pass and detected. For both experiments, individual ion 
dissociation pathway was optimized with regard to collision energy (CE) to minimize 
variations in relative ion abundance due to differences in rates of dissociation. MRM 
transitions and their corresponding declustering potentials (DP) and collision 
energies (CE), listed in Appendix 3, were established for the quantification of 
phospholipids. Triacylglycerols (TAG) were quantified by the selected ion 
monitoring (SIM) method. The difference between MRM and SIM was that the 
former had a pre-set Q1 and Q3 m/z value; while the latter had only pre-determined 
Q3 m/z values.  
 
2.9 Western blot 
2.9.1 Protein extraction 
Four timepoints were set up for protein harvest, namely day 0, day 7, day 14 and day 
21. At each timepoint, triplicate samples of undifferentiated MSC and adipocytes 
were washed with DPBS and DPBS was totally aspirated. Cells were lysed in 250μl 
of RIPA buffer, comprised of 1% (v/v) Triton X-100 (Sigma-Aldrich. St Louis, MO), 
150mM sodium chloride (NaCl (BDH – Merck. Whitehouse Station, NJ), 10mM Tris 
pH7.4, 2mM EDTA (Sigma-Aldrich. St Louis, MO), 0.5% (w/v) Igepal (NP40) 
(Sigma-Aldrich. St Louis, MO), 0.1% (w/v) sodium dodecyl sulphate (SDS) (Merck. 
Whitehouse Station, NJ) and protease inhibitor cocktail at 1:100 dilution (Sigma-
Aldrich. St Louis, MO).  Subsequently, cell lysates were centrifuged at 10000g for 
10 minutes at 4°C. Supernatant (for adipocyte samples, supernatant below the 




2.9.2 Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-
PAGE)  
Protein concentration was determined using bicinchoninic acid (BCA) protein assay 
kit (Pierce-Thermo Scientific. Waltham, MA) as stated in the provided instruction 
manual. 2X Laemmli sample buffer (Sigma-Aldrich. St Louis, MO) was added to 
20μg of protein. Finally, protein samples were boiled at 100°C for 5 minutes. All of 
the prepared protein samples and 10μl of dual-colour protein ladder (BIO-RAD. 
Hercules, CA) were separated on NuPAGE 4-12% Bis-Tris gel (Invitrogen. 
Carlsbad, CA) in 1X MOPS buffer (Invitrogen. Carlsbad, CA) and 500µl of 
NuPAGE antioxidant (Invitrogen. Carlsbad, CA) at 200V for 1 hour.    
 
2.9.3 Membrane transfer 
Upon the completion of gel electrophoresis, the gel, nitrocellulose membrane (BIO-
RAD. Hercules, CA), filter papers (Whatman plc. Maidstone, UK) and fiber pads 
were soaked in transfer buffer (2.5g/l Tris-Base (Sigma-Aldrich. St Louis, MO), 
11.26g/l glycine (BIO-RAD. Hercules, CA) and 20% (v/v) methanol) prior to the 
assembly of the gel and membrane “sandwich” (Figure X). Briefly, the various items 
were placed in the following order: white side of the transfer cassette - fiber pad - 
filter paper - nitrocellulose membrane – gel – filter paper – fiber pad – black side of 
the transfer cassette. Subsequently, the transfer was carried out at 100V for 1.5 hours 
at RT. After the transfer, the membrane was stained with Ponceau S solution (Sigma-
Aldrich. St Louis, MO) to determine the efficiency of the transfer. When the desired 
protein bands were observed, membrane was cut at the appropriate protein size and 
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destained in 1X Tris-buffered saline Tween-20 (TBST: 4.84g/l Tris-Base, 16g/l 
NaCle and 0.2% Tween-20 (Sigma-Aldrich. St Louis, MO)) for 5 minutes on a 
shaker at RT.  
 
2.9.4 Immunoblotting 
Membrane was blocked in using 5% (w/v) non fat dry milk (Anlene. New Zealand) 
in 1X TBST for 1 hour on a shaker. The membrane was incubated with primary 
antibody diluted in 5% milk TBST at the appropriate dilution factor (Table 2-1) 
overnight with gentle shaking at 4°C. The membrane was washed 5 times in TBST 
for 5 minutes each on a shaker at RT. The relevant secondary antibody was also 
diluted in 5% milk TBST at the recommended dilution factor (Table 2-1) and 
incubated with the membrane for 2 hours at RT. The membrane was washed 6 times 
in TBST for 5 minutes each on a shaker at RT. Following this, pat-dried membrane 
was dipped into a solution containing Super Signal® West Pico stable peroxide and 
Luminol / Enhancer solutions (both from Pierce-Thermo Scientific. Waltham, MA) 
in the ratio of 1:1. Finally, in the dark room, the membrane was exposed by placing a 
HyperfilmTM MP (Amersham Biosciences. Piscataway, NJ) on top of it in the 
HypercassetteTM (Amersham Biosciences. Piscataway, NJ) for 1 minute followed by 





Primary Antibodies Dilution Factor
Rabbit polyclonal to VDAC (Cell signalling. Beverly, MA) 1:1000
Mouse Monoclonal to Beta Actin (IgG1k) 
(Chemicon. Temecula, CA) 1:10000
Secondary Antibodies Dilution Factor
Goat polyclonal to Rabbit IgG (Jackson Immunoresearch 
Laboratories Inc. Baltimore, MD); conjugated to HRP 1:10000
Goat polyclonal to Mouse IgG (Jackson Immunoresearch 
Laboratories Inc. Baltimore, MD); conjugated to HRP 1:10000  
Table 2-1: Primary and secondary antibodies used and their dilution factors. 
 
2.9.5 Re-blotting 
For re-probing of membrane with other primary antibodies, the above membrane was 
first washed once in TBST followed by incubation in RestoreTM western blot 
stripping buffer (Pierce-Thermo Scientific. Waltham, MA) for 15 minutes at 37ºC 
with gentle shaking. The membrane was washed again and re-blocked, and re-probed 
as described in 2.9.4 Immunoblotting. 
 
2.10 Data analysis 
2.10.1 Single scan MS 
Lipid chromatograms were combined to generate combined spectra (Figure 2-1) and 
a corresponding spectrum list using MassLynx 4.0 (Waters Corp. Milford, MA). The 
data in plain text files were loaded into Matlab (The MathWorks Inc. Natick, MA) 
for alignment of spectra using correlation-optimised warping (COW) (Nielsen et al., 
1998).  It was a pre-processing method that obtained precise alignment of normalized 
mass spectrometry (MS) spectra from replicate samples. For averaging of spectra 
from replicate independent samples, each ion intensity was normalized to the sum of 
all ion intensities and the normalized data of each replicate was warped against a 
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reference set. After aligning the peaks, the intensity values of individual m/z were 
then averaged to obtain one mean spectrum representative of the replicates. To 
compare between different experimental conditions, the mean spectrum for one 
experimental condition (MSC derived adipocytes (Adipo)) was warped against the 
mean spectrum for the control condition (undifferentiated MSC (UD)). After 
alignment, relative differences in the lipid compositions of the two conditions can be 
computed by simple arithmetic division and represented in the form of ratios on a 
logarithm scale (log10 ratios of adipocyte is to MSC). Consequently, unbiased lipid 
profile changes of MSC differentiation were achieved.   
 
 
Figure  2-1: Combined mass spectrometry (MS) spectra obtained from 
Masslynx software. 





Similarly, lipid chromatograms were combined to generate combined spectra and its 
corresponding spectrum list using Analyst 1.4.2 software (Applied Biosystems. 
Foster City, CA, Foster City, CA). The intensities of individual ions were compared 
with their corresponding internal standard species in order to obtain their analogous 
concentrations. This was subsequently normalized to their respective DNA amounts. 
Finally, the mean concentration of each ion was tabulated and the results were 
expressed as relative content of differentiated MSC (Adipo) compared with that of 
undifferentiated MSC (UD).  
 
2.10.3 Statistical analysis 
Comparison of the undifferentiated MSC (UD) and differentiated MSC (Adipo) was 
performed using the mean of at least three independent biological replicates ± 
standard deviation (SD) from individual samples. Statistical significance between 
them was determined using Student’s t –test, with significance level set at p < 0.05. 
In addition, one way ANOVA followed by Post Hoc tests, Bonferroni and Tukey, 
were also carried out to determine the statistical significance within each condition 




































3.1 Validation of adipogenesis 
3.1.1 Morphological characterization 
Adipogenic differentiation is characterized by the development of lipid droplets (LD) 
within the cell cytoplasm. MSC in the presence of adipogenic cocktail, thereafter 
denotes as Adipo, will develop LD (Pittenger et al., 1999) (Figure 3-1). The number 
of cells with LD increases proportionally with duration of MSC exposure to the 
hormonal cocktail. In addition, larger LD are observed in day 21 adipogenic cultures 
as compared to those from day 14 and day 7. This implies that the LD could have 
either fused together as adipogenesis progresses or they may have grown overtime. 
As for the undifferentiated MSC (UD), their morphology remains relatively the same 
over all three timepoints. Due to the overconfluence of cultures, which is required for 
adipogenesis to take place, the fibroblastic morphology of MSC is not clearly 
distinguishable.  
 
In order to histologically prove that the observed LD are indeed LD constituting 
neutral lipid, Oil Red O (and hematoxylin) staining is employed (Figure 3-2). Oil 
Red O stains neutral lipids red (Pearse, 1968), while hematoxylin stains chromatin 
blue (Mayer, 1903). As expected, all LD are stained red. The low magnification 
images illustrate the extent of Oil Red O staining employed as measure of 
differentiation. The greater intensity of Oil Red O staining in the day 21 adipogenic 
culture is a culmination of a greater proportion of cells containing LD and an 
increase in the size of the LD, thereby validating our light microscopy findings. In 
the UD, there is an absence of red staining. This shows that there is a lack of LD 
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observed in UD, this entails that there is no spontaneous differentiation in these 














Figure  3-1: Morphological observations of undifferentiated MSC (UD) and 
adipocytes (Adipo) at day 7, day 14 and day 21. 
UD: undifferentiated MSC; Adipo: differentiated MSC, adipocytes; Lipid Droplets: 













Figure  3-2: Histochemical Oil Red O and hematoxylin staining of UD and 
Adipo cultures at day 7, day 14 and day 21. 
 
 
3.1.2 Quantitative aspect of adipogenesis 
In the present study, Oil Red O staining is employed to qualitatively estimate the 
extent of differentiation. In order to quantitate extent of MSC adipogenic 
differentiation, Nile Red staining and flow cytometry are employed. Cells detected 
on the FL2 channel are gated and counted by marker 1 (M1). Consistent with our 
microscopic observations (Figures 3-1 and 3-2), no adipocytes were observed in 
undifferentiated MSC cultures (the small amount of cells (< 1%) gated in M1 
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represents auto-fluorescence commonly observed in flow cytometry of UD). For the 
adipogenic samples, 21.95% of cells contain neutral lipids following 7 days of 
adipogenic stimulation, which further increase to 35.40% by day 14 (Figure 3-3A) 
again validating our working hypothesis that extent of adipogenesis increases as a 
function of time. At day 21, the percentage of cells, 36.03%, remains almost similar 
to that of day 14 (Figure 3-3A). This observation does not comply with those seen in 
the histochemical staining using Oil Red O (Figure 3-2). The lower percentage value 
in day 21 is due to the loss of mature adipocytes during the preparation of sample. 
Usually, the cell pellet is collected, stained with Nile red and analysed by flow 
cytometry (Materials and Methods: 2.3). However, unique to day 21 adipogenic 
samples, floating materials are observed in the supernatant. When the floating 
materials are subjected to the same protocol, 88.02% of cells are detected on the FL2 
channel (Figure 3-3B). As these FL2 positive events were of a similar (or greater) 
size and granularity (measured as FSC and SSC respectively) than adipocytes, 
suggests that these were more mature adipocytes which could not be pelleted due to 
their increased buoyancy (larger LD) (Appendix 4). This implies that there is 
probable terminal differentiation at day 21. On the whole, when MSC are subjected 
to adipogenic hormonal inducers for increasing periods of time, there is increasing 
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Figure  3-3: Quantitation of cells containing LD. 
A) FACS analysis of UD and Adipo samples at day 7, 14 and 21. B) FACS analysis 
of floating material in day 21 adipo sample. 
 
3.1.3 Expression of genes related to adipogenesis 
Formation of LD is a phenotypic determination that adipogenesis occurs. To 
demonstrate that adipogenesis also occurred transcriptionally, real time-polymerase 
chain reaction (Real time PCR) is employed to determine changes in mRNA 
expression of adipogenic gene markers. The results are illustrated as a relative 
expression of adipocytes to UD.   
 
C/EBPα is 300 folds more in day 7 adipocytes, which is increased to 400 folds by 
day 14 and finally to 1000 folds at day 21 (Figure 3-4). On the contrary, C/EBPδ 
expression is modestly upregulated in day 7, at about 2.3 folds more than UD. By 
day 14 and day 21, C/EBPδ expression is similar to that of UD (Figure 3-4). This 
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implies that expression of C/EBPδ is probably required during the initial phase of 
adipogenesis. The expression of C/EBPδ could assist in the expression and activation 
of C/EBPα, thus the initial upregulation of C/EBPδ and the perpetual upregulation of 
C/EBPα.   
  
Gene expression of PPARγ1 and PPARγ2 follow a similar trend as C/EBPα. 
PPARγ1 is upregulated by 30 folds in day 7, followed by 50 folds in day 14 and 
finally by 160 folds in day 21 (Figure 3-4). PPARγ2 is also upregulated by 1600 
folds in day 7, which increased to 2300 folds in day 14 and finally 15000 folds in day 
21 (Figure 3-4). PPARγ are transcription factors that regulate adipogenesis. An 
increase in their expression level suggests that there is the occurrence of 
adipogenesis in the differentiated MSC. Since both PPARγ and C/EBPα behave in an 
upward trend manner, this seems to suggest that they may have synergistic 
relationship in regulating adipogenesis. Furthermore, the relative expression for 
PPARγ2 is greater than PPARγ1. This indicates that the differentiated MSC could be 
adipocytes as PPARγ2 is more abundantly expressed in adipocytes.  
 
LPL and aP2 are the downstream adipogenic genes. They are expressed upon 
activation by transcription factors such as C/EBPα and PPARγ. LPL is expressed at 
45000 folds more than UD at day 7. The relative expression decreases to 20000 folds 
at day 14. Nonetheless, LPL is still upregulated in adipocytes at day 14. At day 21, 
LPL relative expression is at 34000 folds (Figure 3-4). Similarly, gene expression of 
aP2 steadily increases from 39000 folds to 125000 folds and finally to 905000 folds 
at days 7, 14 and 21 respectively (Figure 3-4). Such gene expression profile 


















































































































































































Figure  3-4: Comparison of mRNA transcript levels between UD and adipo 
overtime using real time PCR analysis. 
Each bar represents the mean and standard deviation of n = 3 independent samples. * 
represents at least 2.5 fold change and p < 0.05, significantly different between UD 
and Adipo. 
C/EBPa: CCAAT enhancer binding protein α; C/EBPd: CCAAT enhancer binding protein δ; PPARg1: 
peroxisome proliferators-activated receptor γ 1; PPARg2: peroxisome proliferators-activated receptor γ 







3.2 Lipid profiling 
3.2.1 Thin Layer Chromatography (TLC) 
After validating the differentiative status of MSC (i.e. whether it is maintained at an 
undifferentiated state or differentiated state), we can now extract lipids using an 
optimized method to determine the changes in lipid profile between UD and 
adipocytes. TLC is adopted to acquire a general overview of how lipids change when 
MSC undergo adipogenesis. Hexane:Diethyl ether:Formic acid (HEFA) and 
Chloroform:Methanol:Water (C:M:W) systems are used to study the separation of 
neutral and polar lipids respectively. In this study, only day 0 and day 21 samples are 
examined. This is to illustrate the distinct differences in lipid types and amounts 
between UD and adipocytes when equal amounts of total lipids are loaded into each 
system. By comparing the position of each spot to those of standards, identity of 
spots is revealed. Using the NIH ImageJ software, densitometric values of each lipid 
class is derived. After which, these values are normalised to their respective total 
DNA amounts. 
 
Intuitively, neutral lipids are more abundantly available in adipocytes than in UD 
(Figure 3-5A, 3-5B). With the same amount of lipids being loaded for each 
condition, there is a dramatic increase of TAG in day 21 adipocyte samples. In the 
UD samples, there is negligible amount of TAG. This suggests that accumulation of 
TAG is characteristic to adipocytes which comply with the commonly known 
observation. Similarly, there is also more MAG in adipocyte samples than in UD. 
MAG acts as a precursor to TAG synthesis. The presence of more MAG in 
adipocytes suggests its role in TAG biosynthetic pathway to satisfy the increased 
need for TAG. Cholesterol levels remain relatively the same in all three samples. 
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This implies that cholesterol is tightly regulated during adipogenesis which conforms 
to literature reports.   
Unexpectedly, there are lower amounts of phospholipids in the adipocytes than in the 
UD when equal amounts of lipids are spotted for each condition (Figure 3-5C, 3-5D). 
Between day 0 and day 21 UD samples, there is minimal difference in the 
phospholipids changes. This implies that MSC in maintenance culture over 
prolonged periods do not affect the phospholipid levels. However, when MSC 
undergoes adipogenesis, PE decreases by 40% in day 21 samples, while PC 
decreases by 25%. PS possesses the greatest decrease of 50%. This illustrates that 










































































































































































































































































Figure  3-5: General lipid profile. 
A) TLC of day 0, day 21 UD and day 21 Adipo samples using HEFA system. B) 
Densitometry analysis of neutral lipids using NIH ImageJ software. C) TLC of day 0, 
day 21 UD and day 21 Adipo samples using C:M:W system. D) Densitometry 
analysis of phospholipids using NIH ImageJ software. Each bar represents the mean 
and standard deviation of n = 3 independent samples. * represents p < 0.05, 
significantly different between UD and Adipo. 
 
3.2.2 Quantification of triacylglycerols (TAG) species 
As exemplified by TLC, when MSC undergoes adipogenesis, there is accumulation 
of TAG. In order to validate and quantitate the increase in TAG accumulation as 
MSC differentiates down the adipogenic lineage, selected ion monitoring (SIM), one 
of the MS methods, is used. This MS method is programmed such that Q3 is set at 
pre-determined values. Consequently, SIM records intensity of parent ions that 
possess daughter ions of interest upon collision induced dissociation (CID). For each 
resulting ion intensity value, it is normalized to the TAG standard and their 
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corresponding total DNA amounts, followed by the computation of the mean value 
and finally expressed as relative abundance between adipocytes and UD, which is 
illustrated by the coloured bars (Figure 3-6). 
  
At each timepoint, there is more TAG in adipocytes than in UD. Taken together, 
there is increasing abundance of TAG in adipocytes over the three timepoints (Figure 
3-6). This demonstrates the buildup of TAG in adipocytes when adipogenesis 
progresses, which substantiates the results shown in TLC. Amongst the increase, 
there are some TAG species that exhibit greater extent of enhancement. These TAG 
species comprise of fatty acyl chains with three or less double bonds, with the 
majority going to those with three and two double bonds. This suggests that saturated 
and/or monounsaturated fatty acids are preferentially used for the synthesis of TAG 
during adipogenesis. In addition, TAG species that increase dramatically over the 
three timepoints encompass 44 to 58 carbon length. This implies that each of the 




























































** * * * * * ** * ** * * * * * * * *
 
Figure  3-6: Relative abundance of TAG between Adipo and UD at day 7, day 
14 and day 21. 
Each of the colour bars within a row represents mean values from three independent 
samples. Each row across the heat map illustrates a single TAG species. * represents 
p < 0.05, significantly different across three timepoints.  
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3.2.3 Non-targeted profiling of lipids in MSC undergoing adipogenesis 
From the TLC analysis, general overview of changes in lipids during adipogenesis is 
determined. An unexpected decrease of PE, PC and PS are discovered in adipocytes. 
However, the remaining classes of phospholipids, such as PA, PI and PG, are not 
resolved distinctly. In order to investigate deeper into the reduced levels of 
phospholipids during adipogenesis, a more sensitive technique, such as mass 
spectrometry (MS) needs to be adopted.  
 
There are many MS methods available. The strategy in characterizing phospholipid 
profile when MSC undergoes adipogenesis is to first adopt a non-targeted approach 
to obtain an unbiased representation of phospholipids in UD and adipocytes. This is 
carried out using single scan electrospray ionization MS (ESI-MS). Briefly, single 
scan ESI-MS comprises of introducing the sample (in this case, the total lipid 
extract) into the mass spectrometer via ESI method. Individual ionized molecule is 
then allowed to travel through the electric and magnetic fields within the machine 
and finally detected based on its nominal mass to charge (m/z) ratio.  
 
For a particular experimental condition (for example the UD), each ion intensity is 
normalized to the total sum of ion intensities for that condition. Next, the normalized 
data is aligned to a reference set and the mean normalized intensity for each ion is 
determined. Subsequently, the mean spectrum from one experimental condition, such 
as the adipocytes, is warped against the control condition, UD. The relative 
difference between the two conditions is computed, expressed in the logarithm scale 
and illustrated in the form of up/down plots (Figure 3-7). Ions that depict positive 
values indicate that there are more of these ions in the adipocytes than in UD and 
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vice versa. Noise level spans from -0.1 to 0.1 on the y-axis. Consequently, probable 
lipid ions are those beyond this range. By simple arithmetic calculations, logarithm 
ratio of 0.1 refers to a 1.2 folds difference. Hence, ions with at least 1.2 folds 
differences for all timepoints are taken into considerations for other deeper MS 
analysis that is to be discussed in the next section. For simplicity, only ions with 
distinct peaks are illustrated and elaborated in the following up/down plots.  
 
Most of the ions fall between the m/z region of 650 and 900; while some are being 
detected at the lower range of 400 to 650 (Figure 3-7). Previous knowledge tells us 
that phospholipids are ionized to give m/z values within the range of 650 to 900 and 
lysophospholipids at 400 to 650.  
 
At day 7, there are subtle lipid changes between UD and adipocytes (Figure 3-7A). 
Ions that exhibit logarithm ratio (log ratio) of about 0.2 to 0.4 represent those that are 
greater in amounts in adipocytes (i.e. increased). Those ions that are lower in 
amounts in adipocytes (i.e. decreased) also illustrate similar log ratio in the negative 
sense. At day 14, the lipid ion changes become more definite (Figure 3-7B). Not only 
are there more lipid ions that display distinct changes, their relative differences are 
also greater in value, ranging from log ratio of 0.4 to 0.8 and -0.2 to -1. By day 21, 
there are dramatic lipid differences between UD and adipocytes (Figure 3-7C). Lipid 
ions that are more abundant in adipocytes are reduced to three, namely 745.9, 773.9 
and 801. Despite this, these ions illustrate log ratio of 0.4 to 1. This translates to 2.5 
to 10 folds increase. On the other hand, the number of lipid ions that are decreased 
remained the same. However, their relative differences are greatly decreased with 
respect to UD, exhibiting folds decrease of 2.5 to 40. In general, over the three 
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timepoints, there is increasing number of peaks in the “down” plots and their fold 
changes are also greater, especially within the 650 to 900 m/z range. This suggests 
that there is decreasing amounts of phospholipids in adipocytes overtime, which 
validates the TLC results. 
 
Through theoretical calculations, tentative lipid identity can be assigned to each of 
the m/z values. 773.9, which refers to 36:2 PG, is steadily increasing from day 7 to 
day 21 (Figure 3-7; Table 3-1). Interestingly, it is the only lipid ion that increases 
throughout the three timepoints. There are other ions, 745.9 and 801, that start 
increasing from day 14 onwards. They are also PG in nature, namely 34:2 PG and 
38:2 PG respectively (Figure 3-7; Table 3-1). This seems to indicate that PG 
increases as adipogenesis progresses.  
 
Besides the observed increase of lipid ions in adipocytes, majority of the ions 
illustrate a downward trend from day 7 to day 21. 559.4 (18:0 LPI) shows a striking 
decrease from being increased by 2 folds at day 7 to being decreased by 5 folds at 
day 14. By day 21, it decreases by 14 folds (Figure 3-7; Table 3-1). There are also 
other PI ions, such as 571.5 (16:0 LPI) and 865.9 (36:0 PI), that display perpetual 
decrease as adipogenesis progresses. Although 859.8 (36:3 PI) and 885.2 (38:4 PI) 
are more abundant in the adipocytes at day 7 and day 14, their fold change decreases 
from 3 folds to 2.5 folds respectively. By day 21, there is relatively similar amount in 
both UD and adipocytes. This suggests that there is progressive decrease of PI during 





Other than the PIs, there are ions such as 450.4 (16:1a LPE), 690.5 (32:0a PE or 
30:0a PC) and 734.8 (32:0 PS) that demonstrate similar downward trend. Their log 
ratio decreases from about 0.3 to 0.2 during day 7 and day 14 respectively (Figure 3-
7). By day 21, their log ratio further decreases to almost zero (Figure 3-7; Table 3-1). 
This indicates that there is a transient decrease in such phospholipids during 
adipogenesis. Based on their fatty acyl constituents, they can be described as 
saturated phospholipids (i.e. phospholipids comprising of saturated fatty acids). This 
further implies that enzymes, such as desaturases, may be activated at later stage of 
adipogenesis. 
 
Furthermore, there are ions that are perpetually at lower amounts in adipocytes over 
the three timepoints. A majority of these ions fall in the PE (684.8, 702.8, 744.9, 
790.7) phospholipid class, of which 684.8 (32:3a PE) illustrates the most significant 
decrease over the three timepoints (Figure 3-7; Table 3-1). This suggests that PE 
experience tremendous decrease during adipogenesis and that major structural 
changes may have occurred as PE is the second most common structural 
phospholipid in cellular membranes.  
 
Lastly, lipid ions from other classes such as PC (744.9, 766.6) and PS (814.8, 837.8) 
also decrease steadily from day 7 to day 21(Figure 3-7; Table 3-1). This further 






















































Figure  3-7: Up/Down plots of non-targeted phospholipid profile. 
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Increase from Day 14 to Day 21
 
Table 3-1: Summary of phospholipid ion changes. 
 
3.2.4 Tandem MS 
Although the single scan MS provides the spectrum of ions that are present in 
adipocytes and UD, it does not illustrate the identity of these ions, such as the type of 
fatty acyl chains bound to each phospholipid ion. In order to acquire the identity of 
phospholipid species present, tandem MS is used. Briefly, tandem MS comprise of 
fragmenting a single specified ion into its daughter ions via CID. Subsequently, ion 
intensity of all daughter ions are recorded and illustrated in the form of a spectrum 
(Figure 3-8). An example using m/z 885 is demonstrated. Tandem MS of m/z 885 
illustrates the presence of characteristic daughter ions for phospholipid at m/z 78, 96 
and 153, thus verifies that m/z 885 is a phospholipid. In addition, m/z 885 dissociates 
to yield inositol containing fragment at m/z 241. This indicates that m/z 885 is a PI.  
Besides this, m/z 283 and 303 are ions with the next highest ion intensity. Since these 
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two ions translate to FA 18:0 and FA 20:4, they are considered the major fatty acyl 
groups for m/z 885. Hence, m/z 885 is 38:4 PI. Similar analysis is done for the 
remaining m/z values illustrated in the single scan.  
 
Figure  3-8: Tandem MS of m/z 885. 
 
3.2.5 Precursor Ion Scanning (PREIS) 
In addition to tandem MS, PREIS is also carried out to classify ions in their 
respective phospholipid classes. Different phospholipid classes possess different 
daughter fragment ions (Appendix 2). There are six phospholipid classes that are of 
interest. PI and PE each have their own unique fragment structure with m/z value of 
241 and 196 respectively in the negative mode. Ions that fall into the PS category 
loose its amide group, which makes up the m/z value of 87, upon CID. Thus, a 
neutral loss of 87 in the negative mode implies the PS nature in these ions. PG and 
PA possess a fragment structure with m/z value of 153 in the negative mode. For PC, 
it comprises of a product ion of m/z value of 184 in the positive mode. Ions that yield 




Using precursor of 196 as an example, the spectrum of ions illustrates ions that 
generate daughter ion with m/z value of 196 upon CID (Figure 3-9). This shows that 
these ions are of PE in nature since m/z value of 196 reflects the ethanolamine 
headgroup of PE.   After identifying all ions in the spectrum, those that correspond to 
the m/z values in the single scan MS and possess at least 1.5 folds difference are used 
to build the MRM transitions list. PREIS is carried out for all samples and similar 
analysis are done.  
Precursor of 196
Figure  3-9: PREIS spectrum for PE. 
 
3.2.6 Quantification of phospholipid species 
Single scan MS provides a spectrum of ions that are possibly found in UD and 
adipocytes. Results illustrate prominent reduction of phospholipid amounts in 
adipocytes. In order to quantify the extent of phospholipids changes, another MS 
method needs to be adopted. Multiple reaction monitoring (MRM) is a method that 
selects for parent ions of interest that dissociates to form characteristic daughter ions. 
For instance, a particular PI has a parent ion of 885. Upon optimized CID, 885 yields 
daughter ion of 241. Consequently, the programme is designed such that only ions 
that fit into this criterion (also known as the MRM transition) is recorded, which in 
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turn provides the ion intensity for 885 PI. Information retrieved from the single scan 
MS and precursor ion scan is used to build the MRM transition lists (Appendix 3). 
The final ion intensity of each phospholipid species is normalised to their respective 
phospholipid standard and total DNA amounts; followed by the computation of mean 
normalised ion intensity for each phospholipid species. Finally, relative abundance 
between adipocytes and UD, illustrated by coloured bars, is used to demonstrate the 
lipid changes during differentiation. Coloured bars denote values indicated on the 
colour chart. The six phospholipid classes are represented by individual heat plots.  










































Figure  3-10: Relative abundance of PG between Adipo and UD at day 7, day 14 
and day 21. 
Each of the colour bars within a row represents mean values from three independent 
samples. Each row across the heat map illustrates a single PG species. * represents p 
< 0.05, significantly different across three timepoints. 
 
In the single scan MS, although a majority of the ions illustrate reduced amounts in 
the adipocytes, there are some that demonstrate otherwise and they are hypothesized 
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to be PG in nature. In the MRMs, PG species illustrate an upward trend (Figure 3-
10). Consistent with the single scan MS data, 36:2 PG (773.9), 34:2 PG (745.9) and 
38:2 PG (801) prominently display increasing amounts in adipocytes over the three 
timepoints, thereby validating the phenomenon observed in the single scan MS. In 
addition, there are other species of PG evident in the MRM. They too illustrate an 
upward trend. The feature in PG lipids that are increased in adipocytes, is that they 
are comprised of two to three double bonds in their fatty acyl chains. This suggests 
that there are specific types of PG found in adipocytes.  
 
PG are found in mitochondria membranes. Since there are more PG in adipocytes 
over the three timepoints, a likelihood is that there are more mitochondria in 
adipocytes as they differentiate and mature. In order to investigate this hypothesis, 
the expression of a mitochondria-specific protein, voltage-dependent anion channel 
(VDAC) protein is determined by western immunoblotting. Densitometric 
comparison between VDAC value and its respective β-actin is performed to yield the 
relative abundance of VDAC between adipocytes and UD samples. There is a 
transient increase of VDAC in adipocytes at day 7, 14 and 21 (Appendix 5). 
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Figure  3-11: Relative abundance of PI between Adipo and UD at day 7, day 14 
and day 21. 
Each of the colour bars within a row represents mean values from three independent 
samples. Each row across the heat map illustrates a single PI species. * represents p < 
0.05, significantly different across three timepoints. 
 
At day 7, most PI are more abundant in the adipocytes than in the UD. They continue 
to behave in this manner at day 14. However, by day 21, there are significantly lower 
amounts of PI in adipocytes (Figure 3-11). This is also consistent with the single scan 
MS results, where 36:3 PI (859.8) and 38:5 PI (885:2) are increased at day 7 and day 
14. By day 21, no peaks are observed for these ions. Besides this unusual trend, there 
are ions that illustrate perpetual reduction in adipocytes, such as 36:0 PI (865.9) 
which is also evident in single scan MS thereby validating our single scan MS data. 
Although there are some lyso-PI (LPI) and PI that remain slightly more abundant in 
the adipocytes, such as the 20:4 LPI, 20:3 LPI, 32:1 PI, 34:2 PI and 36:4 PI, these PI 
experience tremendous reduction in amounts by day 21. This suggests that there is 
increased metabolism of PI during the later phase of adipogenesis. The resulting 
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metabolites may aid in the maintenance of the adipogenic phenotype and/or the assist 
in the progression into terminal differentiation.  





























































Figure  3-12: Relative abundance of PS between Adipo and UD at day 7, day 14 
and day 21. 
Each of the colour bars within a row represents mean values from three independent 
samples. Each row across the heat map illustrates a single PS species. * represents p 
< 0.05, significantly different across three timepoints. 
 
As exemplified in the TLC, PS are of lower amounts in the adipocyte. The relative 
abundance between adipocytes and UD decreases over time (Figure 3-12). This 
illustrates that PS decrease when MSC differentiate into adipocytes. On the other 
hand, there are some PS that display an upward trend, namely 18:1 LPS, 32:0 PS, 
34:2 PS and 38:1 PS. These PS that increase possess fatty acyl chains that are 16, 18 
and /or 20 carbon length, thereby implying the preferential increase for PS with such 
FA configuration.  
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Figure  3-13: Relative abundance of PA between Adipo and UD at day 7, day 14 
and day 21. 
Each of the colour bars within a row represents mean values from three independent 
samples. Each row across the heat map illustrates a single PA species. * represents p 
< 0.05, significantly different across three timepoints. 
 
Species of PA clearly illustrate a downward trend over the three timepoints (Figure 
3-13). Most of the species start off with being more abundant in the adipocytes at day 
7. As adipogenesis progresses, the levels of PA in adipocytes decline gradually. This 
suggests the decreasing amounts of PA in adipocytes as adipogenic differentiation 
proceeds. Despite the majority of PA species experiencing decrease, 34:2 PA 
increases steadily throughout the three timepointes. Interestingly, it is the only PA 
lipid that exhibits such a phenomenon. This implies the importance of this PA 































































Figure  3-14: Relative abundance of PE between Adipo and UD at day 7, day 14 
and day 21. 
Each of the colour bars within a row represents mean values from three independent 
samples. Each row across the heat map illustrates a single PE species. * represents p 


































































Figure  3-15: Relative abundance of PC between Adipo and UD at day 7, day 14 
and day 21. 
Each of the colour bars within a row represents mean values from three independent 
samples. Each row across the heat map illustrates a single PC species. * represents p 




PE exhibit progressive decrease in adipocytes overtime (Figure 3-14). Similar to PA, 
there are more PE in adipocytes at day 7. By day 14 and day 21, PE decrease in 
adipocytes, leaving only some of the PE to remain higher in the adipocyte. These 
exceptional PE are lyso-PE (LPE) (18:3 LPE, 18:2 LPE, 20:4 LPE), PE (32:2 PE and 
32:1 PE) and plasmalogen PE (34:2p/34:3e PE, 42:1p/42:2e PE). This suggests that 
the increase in some of these PE may be catered for the increase need for membrane 
lipids. As MSC differentiates to adipocytes, MSC undergoes change in cell shape, 
probable increase in cell size and formation of LD.  
 
PC are of lower amounts in adipocyte at all timepoints (Figure 3-15). Similarly, there 
are some PC that display transient increase. 32:2 PC and 32:1 PC increase steadily 
through out the three timepoints. 18:2 LPC also illustrates increase progressively. 
Since PC are also known for their structural function, the observed increase indicates 
the role of these PC to satisfy the structural changes involved during differentiation. 
In addition, there are also plasmalogen PC, such as 34:2p/34:3e PC and 38:5p/38:6e 
PC, that increase slightly overtime, thereby implying that plasmalogen lipids increase 
upon adipogenesis. This increase in plasmalogen lipids is also evident in PE, thus 
presenting a unique lipid signature for adipocyte.  
 
In summary, there are lower amount of phospholipids in adipocytes over the three 
timepoints, which in turn verifies the results illustrated in the TLC and single scan 
MS. In spite of the phenomenal decrease, MRM also demonstrate that there are some 
intriguing lipid species that behaved in the reverse manner. These phospholipids tend 
to be comprised of 32 to 38 carbon chain length with zero to four double bonds in a 
single fatty acyl chain (Table 3-2). This suggests that there is preferential inclusion 
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of such fatty acid into phospholipids when MSC undergoes adipogenesis. Besides the 
unexpected increase of specific phospholipid species, there is a phospholipid class, 
PG, which exhibits a surprising overall increase too. This indicates that PG increases 
upon adipogenic differentiation and can serve as a unique lipid profile to represent 
adipogenesis. 

























36 36:0e PC 36:2 PI,  36:2 PG
36:3 PI,   
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Table 3-2: Summary of phospholipids species that demonstrate an upward 












3.3 Gene expression of Lipins, Lipid Phosphate Phosphatase (LPP) and 
Phospholipases 
In order to understand the cause for the unexpected decrease in phospholipid levels 
during adipogenesis, expression of genes related to the biosynthetic and metabolic 
pathways of phospholipids are investigated. Biosynthesis of phospholipids and TAG 
are closely related and both have a common precursor, PA. Since there is predictable 
increase of TAG and surprising decrease of phospholipids during adipogenesis, it 
will be interesting to study the gene expression level of the enzyme involved in 
determining the fate of PA, lipin. Mammals possess three lipin forms, namely lipin 1, 
lipin 2 and lipin 3 (Peterfy et al., 2001). All three possess phosphatidic acid 
phosphatase (PAP) enzyme activity. In addition to lipin, there is another enzyme that 
also has PAP activity. That is lipid phosphate phosphatase (LPP) and it comprises of 
two isoforms LPPa and LPPb. Gene expressions of these genes are examined. 
Housekeeping genes used and the method of analysis are as described in sections 2.4 
and 3.1.3. The results are expressed in the form of relative expression of adipocytes 
to UD. Only gene expression with at least 2.5 fold change is considered significant.  
 
Lipin 1 is strongly upregulated and its relative expression increases steadily from day 
7 to day 21 (Figure 3-16). At day 7, gene expression of lipin 1 in adipocytes is 2.6 
folds higher than UD. This increases further to 6 folds on day 14. By day 21, the 
relative expression in adipocytes is 12 folds higher than UD. Conversely, there is no 
significant change in expression level for lipin 2 and lipin 3 as adipogenesis 
progresses (Figure 3-16). Similarly, there is also no major change in expression level 
for LPPa and LPPb (Figure 3-16). This implies that lipin 1 exhibits high expression 
level in adipocytes as compared to UD and increasing presence of lipin 1 may be 
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responsible for the shift away from the phospholipids and towards the TAG 
biosynthetic pathway. Hence, the possible cause of decreased phospholipid levels 
during adipogenesis prevails.  
 
Lipin 3





































































































































Figure  3-16: Gene expression levels of lipin 1, lipin 2, lipin 3 LPPa and LPPb 
over three timepoints, day 7, day 14 and day 21 using real time-PCR analysis. 
Each bar represents the mean and standard deviation of n = 3 independent samples. * 
represents at least 2.5 folds change and p < 0.05, significantly different between UD 
and Adipo. 
  
Besides lipins, catabolism of phospholipids can also be used to explain the observed 
decrease in phospholipids during adipogenesis. The enzyme of interest is the 
phospholipase. Amongst the many phospholipases, only those that target the sn-1 and 
sn-2 positions of the phospholipids, such as phospholipase A1 A (PLA1A), 
phospholipase A2 (PLA2) and phospholipase B (PLB) are investigated. Under the 
PLA2 category, there is a variety of PLA2, those that are cytosolic in nature are of 




PLA1A is downregulated at day 7 and day 14 (Figure 3-17), where its expression 
level is 10 and 3 folds lower than UD respectively. By day 21, expression level of 
PLA1A is on par with UD. This illustrates that the expression level of PLA1A is 
silenced early in adipogenesis and returns to baseline as adipogenesis progresses.   
 
Both PLA2 isoforms (PLA2 G4a and PLA2 G6) diplay similar expression pattern 
during adipogenesis. There is no significant change in expression of PLA2s during 
the first 14 days of differentiation, however 3 folds higher levels of PLA2 G4a and 4 
folds higher levels of PLA2 G6 are found in day 21 adipocytes compared to UD 
(Figure 3-17). 
 
PLB does not exhibit any changes in its expression level throughout the three 
timepoints (Figure 3-17). This suggests that PLB may not play a vital role in 
adipogenesis. On the whole, PLA2s possess an upward trend expression level. This 
implies that proteins that act on the sn-2 position of phospholipids are more 
abundantly available, which suggests that the release of fatty acyl at the sn-2 position 

















































































































Figure  3-17: Gene expression levels of PLA1A, PLA2 G4a, PLA2 G6 and PLB 
over three timepoints, day 7, day 14 and day 21 using real time-PCR analysis. 
Each bar represents the mean and standard deviation of n = 3 independent samples. * 
represents at least 2.5 fold change and p < 0.05, significantly different between UD 
and Adipo. 
PLA1A: Phospholipase A1 A; PLA2 G4a: Phospholipase A2 group 4a; PLA2 G6: Phospholipase A2 







































4 Discussions and Future Directions 
Obesity has been viewed as the top ten health problem by the WHO. With the 
increasing prevalence not just in affluent societies, but also in developing countries, 
there is a need to combat this emerging global epidemic. Although dietary habits and 
lifestyle patterns are the major contributing factors of obesity, intrinsic mechanisms 
that lead to obesity should also be taken into consideration, so as to achieve a 
wholesome approach to fighting this problem. Other than hypertrophy of adipocyte, 
hyperplasia of adipocyte is also an etiology of obesity especially in morbid obesity of 
humans and rodents (Hirsch et al., 1989). Recently, progenitors from the bone 
marrow can be recruited to the adipose tissue and differentiate into adipocytes 
(Crossno et al., 2006). This poses as an alternative source of adipocytes contributing 
to obesity, thus it is essential to understand the adipogenic pathway of MSC.  
 
Lipids are more than just energy storage and structural entities. They also function as 
signaling molecules and modulators of inflammatory responses. Importantly, 
changes in cellular lipid composition modify cellular function. For instance, 
supplementation of EPA to T-cells leads to modification of fatty acyl composition of 
phospholipids within their lipid rafts, resulting in suppression of proliferation (Li et 
al., 2006). In addition, changes to membrane lipid composition lead to changes in the 
endocytic organization of lipids intracellularly (Mukherjee & Maxfield, 2004). 
Besides this, alteration to major phospholipid composition in erythrocyte membrane 
is associated to hyperinsulinemia (Candiloros et al., 1996). Identification of lipidome 
changes during MSC adipogenesis provides a fresh perspective, bringing us one step 
closer to understanding the adipose cell development and physiology and battling the 




LD formation is characteristic of adipocytes. Through light microscopy, 
histochemical Oil Red O staining and FACS using Nile red staining, we are able to 
illustrate and validate the differentiation of MSC to adipocytes. As adipogenesis 
progresses, some of the cells exhibit few large LD; while others display many small 
LD.  This observation is consistent with those seen in rat stromal vascular cells 
undergoing adipogenesis, where at later stages of adipogenic differentiation, many of 
the small LD fused together to from larger ones (Nagayama et al., 2007). In addition, 
the fusion of LD to form larger LD is also exemplified in 3T3-L1 where observations 
are made using three-dimensional constructions (Böstrom et al., 2005). This, rules 
out the possibility that LD “disappear” due to vertical movement resulting in one LD 
on top of another. Other than the fusion of small LD to from larger ones, LD may 
also have grown overtime. With each media change in an in vitro setting, there is 
fresh supply of nutrients, this enable more TAG to be synthesized, thus the excess 
TAG are stored in LD leading to the increase in size of LD.  
 
Furthermore, as an additional measure to ensure definitive adipogenesis, expression 
levels of adipogenic genes were also investigated. Consistent with phenotypic 
observations that extent of adipogenesis increases proportionally to time, so too does 
the expression of adipogenic gene markers. When there is upregulation of 
transcription factors, C/EBPα and PPARγ, there is upregulation of adipogenic gene 
markers, LPL and aP2. Coherent with literature findings, the synergistic effects of 
C/EBPα and PPARγ result in the expression of genes necessary for adipocyte 
differentiation (Lefterova et al., 2008). Furthermore, the greater expression levels of 
PPARγ2 as compared to PPARγ1 illustrates that the differentiated MSC are 
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adipocytes, as PPARγ2 is highly and exclusively expressed in adipocytes (Braissant 
et al., 1996; Tontonoz et al., 1994).  
 
Conversely, the expression of C/EBPβ is only increased at day 7. At later timepoints, 
its expression level returns to baseline. This agrees with literature findings that 
C/EBPβ is expressed early during differentiation (Gregoire et al., 1998) and its 
expression level subsequently decreases as adipogenesis progresses (Lane et al., 
1999). Mitotic expansion occurs prior to differentiation (Tang et al., 2003; Reichert 
& Eick, 1999; Yeh et al., 1995). Since C/EBPβ is endogenously expressed during 
clonal expansion (Lane et al., 1999), there is likelihood that C/EBPβ plays a role in 
mitotic expansion. Furthermore, there is evidence demonstrating that C/EBPβ (-/-) 
mouse embryonic fibroblasts cannot undergo mitosis (Tang et al., 2003). 
Phosphorylation of C/EBPβ activates its DNA binding function, which is vital in 
mitotic clonal expansion (Tang et al., 2005). Following this, cells undergo a second 
growth arrest, termed GD (Scott et al., 1982). This marks the point of no return where 
cells are committed and determined to undergo adipogenesis (Otto & Lane, 2005). 
This suggests that MSC subjected to the hormonal inducers are committed to the 
adipogenic lineage after day 7. In addition, reports have illustrated that C/EBPβ 
speeds up the expression of C/EBPα, which in turn expresses adipogenic genes 
(Darlington et al., 1998; Yeh et al., 1995). Once C/EBPα is expressed, C/EBPα can 
regulate its own expression and maintains the adipocyte phenotype (Lin et al., 1993; 
Tang & Lane, 1999). 
 
After verifying the maintenance of undifferentiated state for MSC (UD) and the 
adipogenic state for differentiated MSC (Adipo), characterization of their lipids 
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begins with TLC. TLC has long been adopted to analyse lipids in biological samples. 
Its ease of use and rapid retrieval of data makes TLC the preferred technique in 
providing a general overview of lipid changes between different experimental 
conditions (Wenk, 2004). Under the HEFA system, there is a tremendous increase of 
TAG in day 21 Adipo sample. This is expected of adipocytes due to the formation of 
LD which contain mainly TAG (Martin & Parton, 2005).  
 
Amongst the variety of TAG types that are detected using MS, TAG comprising of 
fatty acyl chains with three or two double bonds and encompassing 44 to 58 carbon 
lengths possess significant upward trend overtime. This suggests that saturated 
and/or mostly monounsaturated FA (MUFA) with 14 to 20 carbons are preferentially 
used for the synthesis of TAG during adipogenesis. AcylCo-A:DAG acyltransferase 
(DGAT) is the enzyme involved in the biosynthesis of TAG (Weiss et al., 1960). A 
lack of DGAT2, one of DGAT isoforms, leads to severe reduction of TAG 
deposition in tissues (Stone et al., 2004), thereby illustrating the significance of 
DGAT in TAG biosynthesis. Stearoyl-CoA desaturase (SCD) is an enzyme 
responsible for the synthesis of MUFA (Ntambi & Miyazaki, 2004). SCD-/- mice 
exhibit considerable decrease in TAG in white adipose tissue and liver (Ntambi et 
al., 2002; Miyazaki et al., 2000). When they are fed with high fat diet, these mice are 
resistant to diet-induce obesity and liver steatosis (Ntambi et al., 2002). In spite of 
these observations, DGAT expression and activity in SCD-/- mice remain similar to 
that of wild type (WT) (Dobrzyn et al., 2005). This indicates the importance of SCD 
in TAG production. Besides this, the close proximity of SCD and DGAT in the ER 
allows enhanced access of MUFA to DGAT for the synthesis of TAG (Man et al., 
2006). Consequently, TAG containing MUFA are more abundantly found in 
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adipocytes. The above described processes can be used to explain the observed 
increase in specific types of TAG. 
 
In addition, there is more MAG in day 21 Adipo sample from the TLC analysis. In 
the MAG pathway, it begins with the acylation of MAG with fatty acyl-CoA 
catalyzed by acylCo-A:MAG acyltransferase (MGAT) to form DAG. Subsequently, 
the same process occurs with DAG in the presence of DGAT to form TAG (Figure 4-
1). Although MAG pathway is commonly demonstrated in the small intestines, it has 
also been shown to occur in adipose tissue (Polheim et al., 1973). There are three 
MGAT isoforms, MGAT1, MGAT2 and MGAT3. All three forms are expressed in 
human adipose tissue (Turkish et al., 2005). Cao et al. have illustrated that the 
activity of MGAT3 is greater than DGAT and proposed that MGAT3 can act as a 
putative TAG synthase (Cao et al., 2007). This suggests that the abundance of MAG 
in adipo samples can be used to satisfy the increased need for TAG.  
 
Besides this, based on TLC results, cholesterol remains relatively the same in all day 
0, day 21 UD and day 21 adipo samples. This is consistent with literature that 
cholesterol is tightly regulated by an elaborate network of systems to bring about 
cellular cholesterol homeostasis (Tabas, 2002; Tall et al., 2002; Simons & Ikonen, 
2000). In membranes, cholesterol has higher affinity to phospholipids and 
sphingolipids with saturated fatty acyl chains (Simons & Vaz, 2004; Simons & 
Ehehalt, 2002). Lipid rafts are regions in the membrane where there are more tightly 
packed due to the presence of saturated hydrocarbon chains in raft sphingolipids and 
phospholipids (Simon & Vaz, 2004). As such, cholesterol has the ability to 
distinguish between raft and non-raft domains (Simons & Ehehalt, 2002). 
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Furthermore, cholesterol plays an integral component in membranes as it helps to 
modulate membrane fluidity and construct semipermeable barrier between cellular 
compartments (Ikonon, 2008). The lack of cholesterol in membranes can lead to 
dissociation of membrane proteins and render these proteins inadequate (Simons & 
Ehehalt, 2002), thereby affecting cellular functions. Besides this, cholesterol itself is 
a toxic compound and is tightly regulated by an array of mechanisms to maintain any 
variation within a narrow range (Goldstein & Brown, 2001). Inability to control the 
levels of cholesterol can lead to pathological diseases, such as atherosclerosis 
(Maxfield & Tabas, 2005). Since adipogenesis is a normal process, one expects 
minimal changes in cholesterol, which is exemplified in the TLC.  
 
On the other hand, TLC under the C:M:W system identifies an overall decrease in 
phospholipids as MSC differentiate into adipocytes. Through the use of MS, more 
detailed examination of phospholipid classes is achieved. Despite a similar overall 
decrease in phospholipids, certain specific phospholipids and phospholipid class (e.g. 
PG) demonstrated to have increased.  
 
Most of the phospholipids that demonstrate transient increase overtime possess a “2 
double bond” configuration (i.e. 32:2a PC, 32:2a PE, 34:2 PG, 34:2 PI, etc.). In 
addition, TAG that exhibit a steady increase throughout time also consists of MUFA 
within them. This suggests that there is preferential inclusion of MUFA to both 
phospholipids and TAG. MUFA can be synthesized endogenously or exogenously 
acquired. In the exogenous context, FA analysis on FBS was carried out using gas 
chromatography-MS (GC-MS). The results show that MUFA is not abundant in FBS 
(Appendix 6). In fact, a large percentage of FA in FBS are saturated FA, such as 
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FA16:0 and FA18:0. This suggests that the source of MUFA derives mainly from de 
novo synthesis. In the ER, SCD acts on fatty acyl-CoA substrates to yield MUFA 
(Ntambi & Miyazaki, 2004). Reports have displayed that SCD is responsible for the 
incorporation of MUFA into TAG of 3T3-L1 (Gomez et al., 2002) and that SCD 
activity increases by 20-100 folds during adipogenic differentiation of 3T3-L1 
(Katsuri & Joshi, 1982). Hence, we have shown that the embodiment of MUFA is 
not only to TAG, but also to phospholipids.  
 
Increased amounts of phospholipids containing MUFA can affect membrane fluidity, 
in turn influence biological functions. Plasma membrane fluidity is maintained by the 
ratio of cholesterol to phospholipids and the ratio of saturated to unsaturated FA 
integrated into phospholipids (Thewke et al., 2000). Since there is an observed 
increase of MUFA-containing phospholipids, membrane fluidity of adipocytes is 
likely to be different from that of MSC. A recent report has illustrated that lipid 
structures regulate function of G protein-coupled receptor (GPCR) (Yang et al., 
2005). GPCR43 is found to be expressed in differentiated 3T3-L1 adipocytes and 
that exogenously added propionate increases the extent of lipid accumulation and 
also elevates the expression of GPCR43 in 3T3-L1 (Hong et al., 2005). Furthermore, 
silencing GPCR43 gene expression through small-interfering RNA (siRNA) 
treatment inhibits adipogenesis (Hong et al., 2005). Similarly, GPR120, another 
member of the GPCR family, is expressed in differentiated 3T3-L1 and the down-
regulation of GPR120 via siRNA also prevents adipogenesis (Gotoh et al., 2007). 
These evidences illustrate that members of the GPCR play a role in modulating 
adipogenesis and their functions can be modified by membrane structures. 
Incorporation of more MUFA containing phospholipids may have modified 
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membrane structure to better suit the localization of respective GPCRs, e.g. GPCR43 
and GPR120, to the membrane, thus allowing more efficient adipogenesis to take 
place.  
 
Other than the increase in phospholipids containing MUFA, some plasmalogen lipids 
are found to be more abundant in adipocytes. Recent report documents the presence 
of plasmalogen PC and PE in adiposomes (Bartz et al., 2007). This suggests that the 
increased plasmalogen lipids observed in MSC-derived adipocytes is due to the 
increased and/or larger LD within them. Plasmalogens have been shown to be 
involved in membrane biogenesis and fusion. Rapid vesicular events are evident at 
membranes high in plasmalogen composition (Gremo et al., 1985). In vitro 
experiments have also shown that membrane fusion occurs more swiftly with 
vesicles containing PE plasmalogens (Glaser & Gross, 1994). This suggests that the 
increased abundance of plasmalogens in adipocytes may be used for the formation of 
LD. In addition, vinyl-ether linkage in plasmalogen has been reported to be more 
susceptible to ROS attack (Hahnel et al., 1999; Zoeller et al., 1999; Hagar et al., 
1996). As a result, presence of plasmalogens can serve as antioxidants, thereby 
shielding neighbouring molecules against ROS attack. With report verifying that 
there is enhanced oxidative phosphorylation in adipocytes (Luo et al., 2008), there 
will thus be increased release of ROS (Gutterman, 2005). The greater abundance of 
plasmalogens in adipocytes can serve as a form of protection against ROS.  
 
Surprisingly, PG steadily increases in adipocytes over the three timepoints despite a 
general decrease in all other classes of phospholipid. Since PG are synthesized and 
found in mitochondrial membranes (Dowan, 1997), increase in PG maybe related to 
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an increase in mitochondria density (number of mitochondria per cell). Western 
immunoblotting of voltage dependent anion channel protein (VDAC), a channel 
protein found at the outer mitochondria membrane (Colombini, 2004), illustrates a 
transient increase in adipocytes overtime (Appendix 5). This seems to imply that 
there is escalating mitochondria as adipogenesis progresses. Literature has 
demonstrated that there is increase of cytochrome c and mitochondrial heat shock 
protein 70 by about 20-30 folds during adipogenesis of 3T3-L1 (Wilson-Fritch et al., 
2003). Similarly, proteomic analysis of human adipose derived stem cells undergoing 
adipogenic differentiation also reveals an increase in similar mitochondrial proteins 
from 8% to more than 18% (DeLany et al., 2005). Light and electron microscopy of 
the adipocyte progeny from human adipose derived stem cells further validate the 
increase in mitochondria numbers in adipocytes (Wilson-Fritch et al., 2003). 
 
Mitochondria biogenesis is usually associated with adaptive thermogenesis in brown 
adipose tissue and skeletal muscles (Butow & Bahassi, 1999). The discovery of 
mitochondria biogenesis in white adipose tissue is unanticipated. PPARγ coactivator-
1α (PGC-1α) is a vital transcription coactivator that is involved in the interaction 
with an array of transcription factors regulating various types of biological functions, 
such as mitochondrial biogenesis and adaptive thermogenesis (Liang & Ward, 2006). 
PGC-1α can also regulate intracellular FA transport and FA β-oxidation (Vega et al., 
2000). There may be factors required for adipogenesis modulating PGC-1α, thereby 
enhancing mitochondrial biogenesis. For instance, there is evidence that pioglitazone 
(TZD and PPARγ agonist) treatment increases the expression of PGC-1α (Bogacka 
et al., 2005). Besides this, dexamethsone and a cAMP elevating agent, affects PGC-
1α expression level. Dexamethasone alone increases expression of PGC-1α slightly, 
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but when coupled with 8-bromo-cAMP, there is a synergistic effect on the expression 
level of PGC-1α (Yoon et al., 2001). As such, there is likelihood that factors 
modulating adipogenesis can also promote mitochondrial biogenesis. As a result, 
increased number of mitochondria prevails. With mitochondria being part of the 
citric acid cycle, they can provide glycerol-3-phosphate (G3P) for the maintenance of 
the rate at which TAG is synthesized (Olswang et al., 2002). The presence of PGC-
1α and increased number of mitochondria allow for β-oxidation of fatty acid in 
mitochondria to occur, thus contributing an alternative source of energy for 
biological functions in adipocytes. 
 
In order to further investigate the relationship between PG, mitochondria and 
adipogenesis, more work needs to be done. Firstly, the observation that 
mitochondrial biogenesis occurs during adipogenesis needs to be verified. This can 
be carried out by determining the mitochondrial copy number through real time PCR 
of genomic and mitochondrial DNA. Furthermore, gene expression level of major 
proteins in mitochondria, such as citrate synthase, can also be monitored to give an 
indication that there may be mitochondrial biogenesis when adipogenic pathway is 
induced. Lastly, the use of Mito Tracker dyes can easily provide a visual effect to 
prove the hypothesis. After the phenomenon of increased mitochondria during 
adipogenesis has been substantiated, thwarting PG synthesis by inhibiting PG-
phosphoric acid (PGP) synthase in MSC undergoing adipogenesis can be one of the 





Apart from the increase in some phospholipid species and PG, the general trend 
observed is a surprising decrease of phospholipids and an expected increase in TAG. 
The decrease in phospholipids observed during adipogenic differentiation appears 
counterintuitive at first. During adipogenic differentiation, the cells hypertrophy 
(grow in size). Thus, one will expect to see increased phospholipids, so as to form 
the larger plasma membrane required to envelope the cellular contents. However, this 
in turn implies that lipids perform only structural functions. Hence, our data also 
support a more dynamic role of lipids during differentiation. 
 
It is classically known that phospholipids and TAG synthesis occurs at the ER and 
sometimes at the mitochondrial membranes. However, when this synthesis is 
measured on microsomal membranes, little amounts of DAG and TAG are detected. 
When the cytosolic fraction is added exogenously into the above in vitro system, 
increased lipids are detected and thus suggest the presence of stimulating factors in 
the cytosol (Hubscher et al., 1967; Stein & Shapiro, 1957). This factor is identified 
as soluble phosphatidic acid phosphatase (PAP) (Johnston et al., 1967; Smith et al., 
1967). Based on the phospholipids and TAG biosynthetic pathway (Figure 4-1), a 
common denominator between the two is PA. Since PA serve as a branch point 
between subsequent phospholipid and TAG synthesis and PAP enzymatic reaction 
operates as a committed step in the production of TAG (Brindley, 1984), regulation 
of PAP activity may determine the fate of PA. There are two types of PAP found in 
yeast and mammalian systems, namely PAP1 and PAP2. PAP1 exists as a cytosolic 
protein that can translocate to the ER (Han et al., 2006). PAP2, later renamed to lipid 
phosphate phosphatases (LPP), is an integral membrane protein (Toke et al., 1999; 
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Toke et al., 1998) that normally does not participate in phospholipid and TAG 
synthesis (Brindley, 2004).  
 
Recent studies have shown that lipin proteins exhibit PAP1 enzyme activity (Donkor 
et al., 2007; Harris et al., 2007; Han et al., 2006). In mammals, there are three lipin 
proteins found in the cytosol, lipin1, 2 and 3 (Peterfy et al., 2001).  All three are 
specific for PA and dependent on Mg2+ (Donkor et al., 2007). Lipin 1 is highly 
expressed in white and brown adipose tissue (Nadra et al., 2008; Verheijen et al., 
2003) and regulates lipid metabolism in mammalian cells (Phan et al., 2005). 
However, little information is known about lipin 2 and 3, except that lipin 2 can be 
found in 3T3-L1 preadipocytes (Grimsey et al., 2008).  
 
In our hands, lipin1 gene expression increases steadily as adipogenesis progresses, 
but there do not seem to have any change in gene expression for lipin 2 and lipin 3. 
Studies have shown that lipin 1 is not only found in the cytosol, but also in the 
nucleus (Peterfy et al., 2005) and that lipin 1 can regulate the expression of 
adipogenic transcription factors, PPARγ and C/EBPα (Phan et al., 2004). As a result, 
maintenance of the adipocyte phenotype reigns. Deficiency of lipin 1 in mice led to 
lipodystrophy and insulin resistance, while an excess resulted in obesity and insulin 
sensitivity (Phan & Reue, 2005). In the work of Grimsey and colleagues, they have 
demonstrated that Lipin 1-depleted 3T3-L1 results in enhanced expression of lipin 2 
but these cells are unable to express aP2 and accumulate lipids within lipid droplets, 
thus implying their inability to differentiate into mature adipocytes. Conversely, 
Lipin 2-depeletd 3T3-L1 allow adipogenesis to persist and in fact there is greater 
expression of aP2 (Grimsey et al., 2008). This suggests the greater importance of 
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lipin 1 than lipin 2 in adipogenesis, thus explains the unchanged expression level of 
lipin 2 when MSC undergoes adipogenesis. Similarly, the unchanged expression 



























Figure  4-1: An overview of phospholipids and TAG biosynthesis. 
CDP-DAG: Cytidine diphosphate-DAG; CMP: Cytidine monophosphate; DHAP: Dihydroxyacetone 
phosphate; DGAT: acyl-CoA:DAG acyltransferase; G3P: Glycerol-3-phosphate; MGAT: acyl-
CoA:MAG acyltransferase; PAP1: phosphatidic acid phosphatase 1; PGP: PG-Phosphoric acid. 
 
In addition, LPP also do possess PAP activity and has a large substrate preference for 
lipid phosphate species (Brindley, 2004). From the gene expression profile of LPPa 
and LPPb, there is no change over the three timepoints. This implies that they may 
not be responsible for the changes seen in phospholipids and TAG. With the 
importance of lipin 1 in adipogenesis and its ability to synthesis TAG, the observed 
phenomenon that there is a general decrease in PI, PS, PE, PC and PA but an 





In addition to lipin and LPP, phospholipases may play a role in the decreased 
phospholipids observed in adipocytes. Mammalian systems possess many 
phospholipases that hydrolyze phospholipids and yield a variety of unique 
phospholipid breakdown products that influence cell function through extracellular 
and/or intracellular receptors (Feige et al, 2006; Hla, 2005; Marrache et al., 2005). 
There are four types of phospholipases that hydrolyze different sn-positions in 
phospholipids (Figure 4-2). Of which, phospholipase A (PLA) and phospholipase B 
(PLB) are of interest. PLB has the ability to act on both sn-1 and sn-2 positions. PLA 
and PLB release fatty acyl chains, which are also active lipid mediators (Zimmerman 
et al., 2002; Funk, 2001). The resulting FA can be used for the synthesis of TAG. In 
addition, there are reports illustrating the ability of FA to modulate adipogenesis. 
Exogenously added medium chain fatty acids, octanoic acid (FA 8:0) and decanoic 
acids (FA 10:0), has been shown to increase lipid accumulation when 3T3-L1 
underwent adipogenesis (Yang et al., 2008; Takenouchi et al., 2004). Similarly, long 
chain fatty acids, linoleic acid (FA 18:2) and oleic acid (FA 18:1), exhibit similar 
phenomenon in human and mouse preadipocytes respectively (Hutley et al., 2003; 




R1 and R2 = alkyl groups

















Figure  4-2: Sites of action by phospholipases on phospholipids. 
PLA1: phospholipase A1; PLA2: phospholipase A2; PLC: phospholipase C; PLD: phospholipase D 
 
Within PLA group of enzymes, there is PLA1 and PLA2. PLA1 hydrolyze 
phospholipids at the sn-1 position to form 2-acyl-lysophospholipids, while PLA2 that 
hydrolyze phospholipids at the sn-2 position to yield 1-acyl-lysophopsholipids. 
Besides this, PLA2 comprise of many different proteins grouped into five classes. 
They are namely secreted PLA2s, cytosolic PLA2s, cytosolic Ca2+-independent 
PLA2s, platelet activating factor (PAF) acetylhydrolases and lysosomal PLA2s 
(Schaloske & Dennis, 2006). Of all the PLA2s, the cytosolic (Group IV) and 
cytosolic Ca2+-independent (Group VI) PLA2s are the most relevant in this study 
because the decreased levels of phospholipids in adipocytes is determined through 
the use of whole cell lipid extract, thus any changes will denotes changes within the 
intracellular environment.  
 
Both PLA2 G4a and PLA2 G6 exhibit upregulation throughout the three timepoints, 
thus imply their possible roles in adipogenesis. A recent report has shown that 
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smaller adipocytes and reduced level of hepatic TAG content are evident in PLA2 
G4a deficient mice (Gruben et al., 2008). In addition, silencing of PLA2 G6a and 
PLA2 G6b in 3T3-L1 results in inhibition of hormone induced adipogenesis (Su et 
al., 2004). These finding imply that these phospholipases are essential for 
adipogenesis which complements the upregulation of PLA2 G4a and PLA2 G6 seen in 
adipogenesis of MSC. In addition, knockdown of PLA2 G6 has been shown to block 
the expression of PPARγ and C/EBPα in 3T3-L1 and the authors suggest that it may 
be the result of lipids produced by PLA2 G6 that elicit such an effect (Su et al., 
2004). 
 
Besides, FA and some metabolites of FA, such as 15dPGJ2 and nitrolinoleic acid, 
serve as PPARγ ligands and in turn promote adipogenesis (Madsen et al., 2005; 
Schopfer et al., 2005; Forman et al., 1995). These evidences show the functional 
aspects of lipids in adipogenesis.  
 
Both PLA2 G4a and PLA2 G6 cleave off FA at the sn-2 position of phospholipids. FA 
in that position are usually unsaturated FA (Yamashita et al., 1997). PLA2 G4a 
preferentially hydrolyses arachidonic acid (AA) at the sn-2 position of phospholipids 
(Krammer et al., 1991; Takayama et al., 1991; Wijkander & Sundler, 1991; Clark et 
al., 1990; Gronich et al., 1990; Leslie et al., 1988). This implies that phospholipids 
with AA within them are greatly decreased. Coincidentally, our results have shown 
that phospholipids with AA within them (i.e. at least 4 double bonds configuration) 
are also decreased overtime. In vivio, the release of AA allows for the synthesis of 
prostaglandins, such as 15dPGJ2, and brings about adipogenesis (Forman et al., 
1995). However, there are other types of phospholipids that are also reduced. PLA2 
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G6 has been reviewed to be able to hydrolyze a wide variety of phospholipids 
(Winstead et al., 2000). The reduction in other forms of lipids may due to PLA2 G6. 
In turn, the release of other types of FA modulating adipogenesis prevails.  
 
Many tissues exhibit PLA1 activity, but physiological functions still remain 
unknown. So far, what is known is that some PLA1 exhibit broad substrate specificity 
such that they are able to hydrolyse phospholipids, TAG and even galactolipids 
(Aoki et al., 2007). On the other hand, there are some, such as PS-specific PLA1 and 
PA-specific PLA1, which elucidate strict substrate specificities (Sonoda et al., 2002; 
Higgs et al., 1998). In the database, only one PLA1 hit is returned which is the first 
mammalian PLA1 cloned, PS-specific PLA1 (denoted as PLA1A). PLA1A hydrolyses 
PS specifically at the sn-1 position to yield 2-acyl lysoPS (Higgs et al., 1997). 
Induction of endotoxin shock in rats through injection with lipopolysaccharide 
results in immense upregulation of PLA1A gene expression, thus suggesting the role 
of PLA1A in pathological states (Deaciuc et al., 2004). In addition, the released 
lysophosphatidylserine (LPS) has been shown to be involved in T-cell growth 
suppression and mast cell activation (Lourenssen & Blennerhassett, 1998; Bellini & 
Bruni, 1993). These evidences point towards the notion that PLA1A and its 
breakdown products are related to immunological response and function.  
 
Recent report has demonstrated that LPS stimulate glucose uptake in 3T3-L1, which 
suggests the involvement of LPS in adipogenesis (Yea et al., 2009). Coincidentally, 
18:1 LPS exhibits an upward trend. The other species of PS display a general 
decrease overtime. This suggests that there is likely hydroxylation of PS to LPS and 
thus the presence of PLA1A activity. Although there is downregulation of PLA1A 
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gene expression, gene expression level does not always translate to protein function 
and activity (Gygi et al., 1999). There is likelihood that due to the high PLA1A 
activity upon adipogenic induction that there is no need for constant expression of 
PLA1A gene, thus the observed downregulation prevails. However, protein activity 
cannot be sustained for perpetual length of time. Overtime, gene of PLA1A will still 
need to be expressed to bring about the PLA1A activity. Hence, gene expression level 
for PLA1A returns to baseline at day 21. More research needs to be done to 
investigate this phenomenon.  
 
Since adipose tissue is regarded as an endocrine organ and PLA2 illustrates 
upregulation during adipogenesis, there is likelihood that the resultant products may 
be secreted out of cells and modulate adipogenesis in neighbouring cells. Evidence 
has demonstrated that fatty acid and its metabolites, such as eicosanoids, behave as 
bioactive lipid mediators (Zimmerman et al., 2002; Funk, 2001). Hence, it will be 
interesting to investigate the profile of FA and eicosanoids in the extracellular 
domain. Modification of adipogenic cocktail to exclude dexamethasone is required as 
dexamethasone acts as both a cyclooxygenase 1 and cyclooxygenase 2 inhibitor, 
thereby preventing the production of eicosanoids. Besides this, exogenous addition 
of FA can be carried out to determine the effects of FA in adipogenesis of MSC.  
 
Identification of lipid characteristics during adipogenesis allows for deeper 
understanding of how adipogenesis takes place in a lipid-related manner. The 
presence of unique trends, such as decreased amounts of phospholipids in adipocytes, 
increasing trend of PG and selective incorporation of fatty acids to phospholipids in 
adipocytes, enable the targeting of pathways associated to these trends. 
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Consequently, combating obesity becomes more efficient. Besides this, current 
literatures have suggested that a balance between osteogenesis and adipogenesis 
within bone marrow is essential for the healthy development of bone (Nuttall & 
Gimble, 2004; Nuttall & Gimble, 2000). Adopting the same methods for the lipid 
profiling of MSC-derived adipocytes to MSC-derived osteoblasts, followed by 
comparison between the profiles can help discover lipid species that exhibited 
significant differences. Further probing of this effect will allow for better 
understanding of the relationship between the two progenies. As a result, 
development of improved treatment for bone dysfunction-related diseases, such as 
osteoporosis and osteopenia, can be achieved.   
 
In conclusion, the results demonstrate generally lower amounts of phospholipids in 
adipocytes with a surprising increase in PG and selective inclusion of fatty acids into 
phospholipids. This unique lipid fingerprint for adipocytes provides the first step to 





































The lipid profiling of MSC undergoing adipogenesis has revealed that in spite of the 
expected increase in TAG, there is also a surprising decrease in phospholipids during 
adipogenesis. This decrease appears to be counterintuitive at first. During adipogenic 
differentiation, the cells hypertrophy (grow in size). Thus, one will expect to see 
increased phospholipids, so as to form the larger plasma membrane required to 
envelope the cellular contents.  However, this in turn implies that lipids perform only 
structural functions. Hence, our data also support a more dynamic role of lipids 
during cellular function.  
 
The gene expression levels of lipin 1 and phospholipases demonstrated that these 
proteins may be responsible for the observed decrease in phospholipids. Literatures 
have also illustrated the importance of these enzymes during adipogenesis. It will be 
interesting to investigate further how these enzymes act during adipogenesis so as to 
understand the intrinsic mechanisms involved and thus add more insight to the 
adipogenic cascade. Besides this, adipose tissue has been regarded as an endocrine 
organ. Research on the type of factors released during adipogenesis of MSC can 
provide more information on the interactions between MSC, preadipocytes and 
adipocytes. As a result, identification of factors that commit MSC to the adipogenic 
lineage may be discovered.  
 
Contrary to the general decrease in phospholipids, there is a class of phospholipids 
that exhibited an overall increase, PG. The increase in PG may indicate an increase 
in mitochondria, which is exemplified through the transient increase in VDAC 
protein as adipogenesis progresses. This finding is rather unexpected as mitochondria 
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biogenesis has usually been associated to brown adipose tissues. It is only in recent 
reports that scientists too discover this exceptional phenomenon in white adipose 
tissues. More works are underway to explore this observation.  
 
In addition, there are some species of phospholipids that increased overtime. 
Similarly, amongst the more abundantly available TAG in adipocytes, those TAG 
species that display progressive increase encompass similar characteristics to 
particular phospholipids types that increase overtime. Most of them are made up of 
MUFA. This finding suggests that there is preferential incorporation of MUFA to 
TAG and phospholipids and that this process is occurring via the de novo pathway. 
Further development in this area may reveal exciting revelations on the biosynthetic 
pathways of phospholipids and TAG. 
 
Current literatures have suggested that a balance between osteogenesis and 
adipogenesis within bone marrow is essential for the healthy development of bone 
(Nuttall & Gimble, 2004; Nuttall & Gimble, 2000). Adopting the same methods for 
the lipid profiling of adipocyte-derived MSC to osteoblast-derived MSC, followed by 
comparison between the profiles can help discover lipid species that exhibited 
significant differences. Further probing of this effect will allow for better 
understanding of the relationship between the two progenies. As a result, 
development of improved treatment for bone dysfunction-related diseases, such as 
osteoporosis and osteopenia, can be achieved.   
 
Taken together, lipid profiling of MSC undergoing adipogenesis presents the unique 
lipid fingerprints of cells at distinct differentiative stages. In-depth analysis of the 
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abundant information acquired can reveal interesting and novel observations, thus 
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Gene name Primer Name Primer (5' → 3') 
Primer 
length 
18SrRNA F GACTCAACACGGGAAACCTC 20 18S ribosomal RNA 
18SrRNA R AGCATGCCAGAGTCTCGTTC 20 
β-Actin F CACACTGTGCCCATCTACGA 20 β-Actin 
β-Actin R GTGGTGGTGAAGCTGTAGCC 20 
GAPDH F CCCTTCATTGACCTCAACTACAT 23 Glyceraldehyde-3-
phosphate dehydrogenase GAPDH R TCCTGGAAGATGGTGATGG 19 
HMBS F AGGATGGGCAACTGTACCTG 20 Hydroxymethylbilane 
synthase HMBS R TCGTGGAATGTTACGAGCAG 20 
HPRT1 F TGAGGATTTGGAAAGGGTGT 20 Hypoxanthine 
phosphoribosyltransferase 
1 HPRT1 R AATCCAGCAGGTCAGCAAAG 20 
PPARG1-2 F CTTCCATTACGGAGAGATCC 20 Proliferator peroxisome 
activated receptor γ 1 PPARG1 R AAAGAAGCCGACACTAAACC 20 
Proliferator peroxisome 
activated receptor γ 2 PPARG2 R GCGATTCCTtCACTGATAC 19 
C/EBPa F GAGGAGGGGAGAATTCTTGG 20 CCAAT Enhancer binding 
protein α C/EBPa R TCTCATGGGGGTCTGCTGTA 20 
C/EBPd F CTGTCGGCTGAGAACGAG 18 CCAAT Enhancer binding 
protein δ C/EBPd R GAGGTATGGGTCGTTGCTG 19 
LPL F CAGCCAGGATGTAACATTGG 20 Lipoprotein lipase 
LPL R AGGCTTCCTTGGAACTGCAC 20 
aP2 F  TACTGGGCCAGGAATTTGAC 20 Adipocyte fatty acid 
binding protein aP2 R GTGGAAGTGACGCCTTTCAT 20 
PLA1 F AGTTCTGCACTGCCCTTTTG 20 Phospholipase A 1 
PLA1 R AATGCAGGGAGATGTGTCCT 20 
PLA2-G4A F AGCCATATTGGGTTCAGGTG 20 Phospholipase A 2 Group 
4A PLA2-G4A R GGCCCTTTCTCTGGAAAATC 20 
PLB F TCAGGAGAAGACCCACCAAC 20 Phospholipase B 
PLB R TCGGGAGTGAGACTTGCTG 19 
LPIN1F AGTGACCAATCGCCAACTCT 20 Lipin 1 
LPIN1R TCCGTCTTGTTTGCTGTCTG 20 
LPIN2F ACCTTTTCACGTTCGGTTTG 20 Lipin 2 
LPIN2R CCAAAGGGGTGTCAATATCTTT 22 
LPIN3F TCAGTGAAGGGTGACAGCAG 20 Lipin 3 
LPIN3R GTGTGTCATGTGCTGAGATGC  21 
LPPa F GACTGCGGCCTCACTTCTT 19 Lipid Phosphate 
Phosphatase a LPPa R AAACAGCATGCAGTACATGGAG 22 
LPPb F AAATGACGCTGTGCTCTGTG 20 Lipid Phosphate 
Phosphatase b LPP2b R CTGTGAAAGACTGGCTGATGG 21 
 








                           
 



















































































































































































  Phosphatidylcholine        
           
PC 12:2 LPC 436.6 184.1 90 50 
PC 14:1p LPC 450.6 184.1 90 50 
PC 14:2 LPC 464.6 184.1 90 50 
PC 16:0e LPC 482.6 184.1 90 50 
PC 16:6 LPC 484.6 184.1 90 50 
PC 16:0 LPC 496.6 184.1 90 55 
PC 18:0e LPC 510.6 184.1 90 50 
PC 18:2 LPC 520.6 184.1 90 50 
PC 18:1 LPC 522.6 184.1 90 50 
PC 18:0 LPC 524.6 184.1 90 50 
PC 20:0p / 20:1e LPC 536.6 184.1 90 50 
PC 20:0e LPC 538.6 184.1 90 50 
PC 20:4 LPC 544.6 184.1 90 54 
PC 20:3 LPC 546.6 184.1 90 54 
PC 26:0e PC 636.7 184.1 90 60 
PC 28:4p PC 638.7 184.1 90 60 
PC 30:4e PC / 30:3p PC 668.8 184.1 90 60 
PC 30:3e / 30:2p PC 670.8 184.1 90 60 
PC 28:1 PC 676.7 184.1 90 60 
PC 32:0p / 32:1e PC 703.9 184.1 90 60 
PC 32:0e PC 705.9 184.1 90 60 
PC 32:2 PC 717.9 184.1 90 60 
PC 32:1 PC 719.9 184.1 90 60 
PC 32:0 PC 718.9 184.1 90 60 
PC 34:2p / 34:3e PC 720.9 184.1 90 60 
PC 34:1p / 34:2e PC 729.9 184.1 90 60 
PC 34:0p / 34:1e PC 730.9 184.1 90 60 
PC 34:3 PC 732.9 184.1 90 60 
PC 34:2 PC 734.9 184.1 90 60 
PC 34:1 PC 742.9 184.1 90 60 
PC 36:4p PC 744.9 184.1 90 60 
PC 36:3p / 36:4e PC 746.9 184.1 90 60 
PC 36:2p / 36:3e PC 756.9 184.1 90 60 
PC 36:1p / 36:2e PC 758.9 184.1 90 60 
PC 36:0p / 36:1e PC 760.9 184.1 90 60 
PC 36:5 PC 766.9 184.1 90 60 
PC 36:4 PC 768.9 184.1 90 60 















  Phosphatidylcholine        
           
PC 36:3 PC 770.9 184.1 90 60
PC 36:2 PC 772.9 184.1 90 60
PC 36:1 PC 774.9 184.1 90 60
PC 38:4p / 38:5e PC 780.9 184.1 90 60
PC 38:3p / 38:4e PC 782.9 184.1 90 60
PC 38:2p / 38:3e PC 784.9 184.1 90 60
PC 38:6 PC 786.9 184.1 90 60
PC 38:5 PC 788.9 184.1 90 54
PC 38:4 PC 794.9 184.1 90 54
PC 38:3 PC 796.9 184.1 90 54
PC 40:4p / 40:5e PC 798.9 184.1 90 54
PC 40:3p / 40:4e PC 806.9 184.1 90 54
PC 40:2p / 40:3e PC 808.9 184.1 90 54
PC 40:1p / 40:2e PC 810.9 184.1 90 54
PC 40:0e PC 812.9 184.1 90 54
PC 40:6 PC 813.9 184.1 90 54
PC 40:5 PC 815.9 184.1 90 54
PC 13:0 PC / 14:0e PC 822.9 184.1 90 54
PC 30:1 / 31:1e / 31:0p PC 824.9 184.1 90 54
PC 30:0 / 31:0e PC 826.9 184.1 90 54
PC 30:2 PC 827.9 184.1 90 54
PC 34:4e / 34:3p PC 828.9 184.1 90 54
PC 36:0e PC 832.9 184.1 90 65
PC 36:0 / 38:6p PC 834.9 184.1 90 54
PC 38:5p  / 38:6e PC 836.9 184.1 90 54
PC 38:2 PC 814.8 184.1 90 60
PC 38:1 PC 816 184.1 90 60
PC 40:0 PC 846.1 184.1 90 60
PC 42:5 / 44:12e / 44:11p PC 848.2 184.1 90 60
PC 42:4 / 44:11e / 44:10p PC 850.1 184.1 90 60
PC 42:3 / 44:10e / 44:9p PC 852.1 184.1 90 60
 


















           
  Phosphatidic acid        
PA  32:2 PA 643.7 153 -80 -40
PA  34:2 PA 671.7 153 -80 -30
PA  34:1 PA 673.7 153 -80 -50
PA  34:3 PA 669.8 153 -80 -50
PA  36:1 PA 701.8 153 -80 -50
PA  36:0 PA 703.8 153 -80 -50
PA  38:4 PA 723.8 153 -80 -50
PA  38:0 PA 731.9 153 -80 -50
PA  40:6 PA 747.9 153 -80 -50
PA  40:5 PA  749.9 153 -80 -50
PA  40:4 PA 751.9 153 -80 -50
PA  42:6 PA  775 153 -80 -50
PA  42:5 PA  777 153 -80 -50
PA  32:3 PA 796.9 153 -80 -40
           
  Phosphatidylglycerol        
LPG 16:1 LPG 481.2 153 -80 -40
PG 32:2 PG 717.8 153 -80 -50
PG 34:3 PG 743.9 153 -80 -50
PG 34:2 PG 745.9 153 -80 -50
PG 34:1 PG 747.9 153 -80 -50
PG 34:0 PG 749.9 153 -80 -50
PG 36:4 PG 769.9 153 -80 -50
PG 36:2 PG 773.9 153 -80 -50
PG 36:1 PG 775 153 -80 -50
PG 36:0 PG 777 153 -80 -50
PG 38:2 PG 801 153 -80 -50
PG 38:1 PG 803 153 -80 -50
PG 42:6 PG 849.1 153 -80 -50
PG 42:5 PG 851.1 153 -80 -50
PG 42:1 PG 859.1 153 -80 -50
           
PG 36:3 PG 771.8 153 -90 -55
 

















           
  Phosphatidylinositol        
PI 17:0 LPI 585.7 241 -90 -55
PI 16:0 LPI 571.7 241 -90 -55
PI 18:0 LPI 599.7 241 -90 -55
PI 20:4LPI 619.7 241 -90 -55
PI 32:1 PI 807.8 241 -115 -55
PI 33:1 PI 821.8 241 -115 -55
PI 34:7 PI 823.8 241 -115 -55
PI 34:2 PI 833.8 241 -115 -55
PI 34:1 PI 835.8 241 -115 -55
PI 35:1 PI 849.8 241 -115 -55
PI 36:4 PI 857.8 241 -115 -55
PI 36:3 PI 859.8 241 -115 -55
PI 36:2 PI 861.9 241 -115 -55
PI 36:1 PI 863.9 241 -115 -55
PI 37:4 PI 871.9 241 -115 -55
PI 37:3 PI 873.9 241 -115 -55
PI 38:5 PI 883.9 241 -115 -55
PI 38:4 PI 885.9 241 -115 -60
PI 38:3 PI 887.9 241 -115 -60
PI 39:4 PI 899.9 241 -115 -60
PI 39:3 PI 901.9 241 -115 -60
PI 40:6 PI 909.9 241 -115 -55
PI 40:5 PI 911.9 241 -115 -55
PI 40:4 PI 913.9 241 -115 -55
PI 40:2 PI 917.9 241 -115 -55
PI 20:3 LPI 621.7 241 -90 -55
PI 34:0 PI 837.8 241 -115 -55
PI 36:0 PI 865.9 241 -115 -55
PI 38:2 PI 889.9 241 -115 -60
PI 38:1 PI 891.2 241 -115 -60
 





















           
  Phosphatidylserine        
PS 16:1 LPS 494.7 407.7 -80 -25
PS 16:0 LPS 496.7 409.7 -80 -25
PS 17:1 LPS 508.7 421.7 -80 -25
PS 17:0 LPS 510.7 423.7 -80 -25
PS 18:1 LPS 522.7 435.7 -80 -25
PS 18:0 LPS 524.7 437.7 -80 -25
PS 34:2 PS 758.6 671.6 -80 -25
PS 34:1 PS 760.6 673.6 -80 -25
PS 36:2 PS 786.6 699.6 -80 -25
PS 36:1 PS 788.6 701.6 -80 -25
PS 38:4 PS 810.6 723.6 -80 -25
PS 38:3 PS 812.6 725.6 -80 -25
PS 40:7 PS 832.6 745.6 -80 -25
PS 40:6 PS 834.6 747.6 -80 -25
PS 40:5 PS 836.6 749.6 -80 -25
PS 32:0 PS 734.8 647.8 -80 -25
PS 36:0 PS 790.7 703.7 -80 -25
PS 38:5 PS 808 721 -80 -25
PS 38:2 PS 814.8 727.8 -80 -25
PS 38:1 PS 816 729 -80 -25
PS 40:4 PS 838.8 751.8 -80 -25
PS 40:3 PS 840.1 753.1 -80 -25
PS 40:1 PS 844.1 757.1 -80 -25
PS 40:0 PS 846.1 759.1 -80 -25
PS 42:5 PS 864.9 777.9 -80 -25
PS 42:4 PS 866.9 779.9 -80 -25
 


























           
  Phosphatidylethanolamine        
PE 16:0p / 16:0e LPE 436.5 196.1 -80 -30
PE 16:1 LPE 450.5 196.1 -80 -30
PE 16:0 LPE 452.5 196.1 -80 -30
PE 18:1p / 18:2e LPE 462.5 196.1 -80 -40
PE 18:0p / 18:1e LPE 464.5 196.1 -80 -30
PE 18:2 LPE 476.5 196.1 -80 -50
PE 18:1 LPE 478.5 196.1 -80 -50
PE 18:0 LPE 480.5 196.1 -80 -55
PE 20:0p / 20:1e LPE 492.5 196.1 -90 -55
PE 20:4 LPE 500.5 196.1 -90 -55
PE 22:6 LPE 524.6 196.1 -90 -55
PE 32:0p PE 660.8 196.1 -90 -55
PE 32:0e PE 662.8 196.1 -90 -55
PE 32:2 PE 686.8 196.1 -90 -55
PE 32:1 PE 688.8 196.1 -90 -55
PE 32:0 PE 690.8 196.1 -90 -55
PE 34:2p / 34:3e PE 698.8 196.1 -90 -55
PE 34:1p / 34:2e PE 700.8 196.1 -100 -55
PE 34:2a PE 714.8 196.1 -100 -55
PE 34:1a PE 716.8 196.1 -110 -55
PE 36:5p PE 720.8 196.1 -110 -55
PE 36:4p PE 722.8 196.1 -115 -55
PE 36:2p / 36:3e PE 726.8 196.1 -115 -55
PE 36:1p / 36:2e PE 728.8 196.1 -115 -55
PE 36:4 PE 738.8 196.1 -115 -55
PE 36:3 PE 740.8 196.1 -115 -55
PE 36:2 PE 742.8 196.1 -115 -55
PE 36:1 PE 744.8 196.1 -115 -55
PE 36:0 / 38:6p PE 746.8 196.1 -115 -55
PE 38:5p / 38:6e PE 748.8 196.1 -115 -55
PE 38:4p / 38:5e PE 750.8 196.1 -115 -55
PE 38:1p / 38:2e PE 756.8 196.1 -115 -55
PE 38:0e PE 760.8 196.1 -115 -55
 

















           
  Phosphatidylethanolamine        
PE 38:6 PE 762.8 196.1 -115 -55
PE 38:5 PE 764.8 196.1 -115 -55
PE 38:4 PE 766.8 196.1 -115 -55
PE 38:0 / 40:6p PE 774.8 196.1 -115 -55
PE 40:5p / 40:6e PE 776.8 196.1 -115 -55
PE 40:4p / 40:5e PE 778.8 196.1 -115 -55
PE 40:6 PE 790.8 196.1 -115 -55
PE 40:5 PE 792.8 196.1 -80 -40
PE 16:0e PE 438.1 196.1 -80 -30
PE 18:3 PE 474.6 196.1 -80 -50
PE 32:1p / 32:1e PE 672.8 196.1 -80 -30
PE 32:3 PE 684.8 196.1 -90 -55
PE 34:0p / 34:1e PE 702.8 196.1 -100 -55
PE 36:3p / 36:4e PE 724.8 196.1 -115 -55
PE 38:1 PE 772.9 196.1 -115 -55
PE 42:3p / 42:3e PE 808 196.1 -115 -55
PE 42:2p / 42:3e PE 810 196.1 -115 -55
PE 42:1p / 42:2e PE 812 196.1 -115 -55
PE 42:0p / 42:1e PE 814.8 196.1 -115 -55
PE 42:0e PE 816 196.1 -115 -55
 
Table A3-2: MRM transition lists in the negative mode (cont’d). 
 









DAPA std 40:8 PA 743.8 153 -80 -40
DMPG std 28:0 PG 665.6 153 -90 -50
Di-C8 PI std 16:0 PI 585.5 241 -90 -55
DMPS std 28:0 PS 678.6 591.6 -80 -25
DMPE std 28:0 PE 634.6 196.1 -90 -50
DMPC std  28:0 PC 678.8 184.1 90 50
 
















49:2 834.8 54:4 900.9 
49:1 836.8 54:3 902.9 
42:1 738.8 54:2 904.9 
42:0 740.8 54:1 906.9 
44:2 764.8 54:0 908.9 
44:1 766.8 56:9 918.9 
44:0 768.8 56:8 920.9 
46:3 790.8 56:7 922.9 
46:2 792.8 56:6 924.9 
46:1 794.8 56:5 926.9 
46:0 796.8 56:3 930.9 
48:4 816.8 56:2 932.9 
48:3 818.8 56:1 934.9 
48:2 820.8 56:0 936.9 
48:1 822.8 58:10 944.9 
48:0 824.8 58:9 946.9 
49:3 832.8 58:8 948.9 
49:2 834.8 58:7 950.9 
49:1 836.8 58:6 952.9 
50:5 842.8 58:3 956.9 
50:4 844.8 60:10 972.9 
50:3 846.8 60:9 974.9 
50:1 850.8 60;8 976.9 
50:0 852.8 60:7 978.9 
51:4 858.9 60:6 980.9 
51:3 860.9 60:5 982.9 
51:2 862.9   
51:1 864.9   
52:6 868.9   
52:5 870.9   
52:4 872.9   
52:3 874.9   
52:2 876.9   
52:1 878.9   
52:0 880.9   
54:7 894.9   
54:6 896.9   
54:5 898.9   
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Figure A4-1: Forward scatter (FSC) and side scatter (SSC) of UD and Adipo at 

























































































































































Figure A5-1: VDAC protein in UD and Adipo samples overtime.  
A) Western blot of VDAC and β-actin. B) Densitometic analysis of bands. 


















































Figure A6-1: FA analysis of FBS.  
































Figure A7-1: Raw TOF spectra for UD and Adipo samples  
Representative raw data profiles of 1 data set for Day 21 samples. Day 7 and Day 14 
profiles are not presented here.  
